

08/25/00

08-28-00

Docket No. 62683/JPW/JML

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Honorable Assistant Commissioner for Patents  
Washington, D.C. 20231  
BOX: PATENT APPLICATION  
S I R:

**August 25, 2000**

Office U.S. Pro  
09/648389

Transmitted herewith for filing are the specification and claims of the patent application of:

David Pinsky, David M. Stern and Shi-Fang Yan for  
Inventor(s)

**METHODS FOR SUPPRESSING EARLY GROWTH RESPONSE -1 PROTEIN (Egr-1) TO REDUCE VASCULAR INJURY**  
**Title of Invention IN A SUBJECT**

Also enclosed are:

  X     19   sheet(s) of       informal   X   formal drawings.

X Oath or declaration of Applicant(s). (Unsigned)

  X   A power of attorney (Unsigned)

- An assignment of the invention to

## A Preliminary Amendment

\_\_\_\_\_ A verified statement to establish small entity status under 37 C.F.R.  
§1.9 and §1.27.

The filing fee is calculated as follows:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT

|   | NUMBER<br>FILED |   | NUMBER<br>EXTRA* |   | RATE            |                 | FEE |                 |                 |
|---|-----------------|---|------------------|---|-----------------|-----------------|-----|-----------------|-----------------|
|   |                 |   |                  |   | SMALL<br>ENTITY | OTHER<br>ENTITY |     | SMALL<br>ENTITY | OTHER<br>ENTITY |
| Total Claims  | 27-20           | = | 7                | X | \$ 9.00         | \$18.00         | =   | \$              | \$ 126          |
| Independent<br>Claims   | 2 -3            | = | 0                | X | \$39.00         | \$78.00         | =   | \$              | \$ 0            |
| Multiple Dependent<br>Claims Presented: <u>      </u> Yes <u>  X  </u> No |                 |   |                  |   | \$130.00        | \$260.00        | =   | \$              | \$ 0            |
| *If the different in Col. 1 is<br>less than zero, enter "0" in<br>Col. 2  |                 |   |                  |   | BASIC FEE       |                 |     | \$              | \$ 690          |
|   |                 |   |                  |   | TOTAL FEE       |                 |     | \$              | \$816           |

Applicants: David Pinsky, David M. Stern and Shi-Fang Yan

U.S. Serial No.: Not Yet Known

Filed : Herewith

Letter of Transmittal

Page 2

☒ A check in the amount of \$ 816.00 to cover the filing fee.

☐ Please charge Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_.

☒ The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the following or credit any over-payment to Account No. 03-3125:

☒ Filing fees under 37 C.F.R. §1.16.

☒ Patent application processing fees under 37 C.F.R. §1.17.

☐ The issue fee set in 37 C.F.R. §1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. §1.311(b).

☐ Three copies of this sheet are enclosed.

☐ A certified copy of previously filed foreign application No. \_\_\_\_\_ filed in \_\_\_\_\_ on \_\_\_\_\_ Applicant(s) hereby claim priority based upon this aforementioned foreign application under 35 U.S.C. §119.

☒ Other (identify) One extra set of loose formal drawings and an Express Mail Certificate of Mailing bearing the label # EJ 900 852 229 US dated August 25, 2000.

Respectfully submitted,

Jane M. Love

John P. White  
Registration No. 28,678  
Jane M. Love  
Registration No. 42,812  
Attorney for Applicants  
Cooper & Dunham, LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

*Application  
for  
United States Letters Patent*

**To all whom it may concern:**

Be it known that **David Pinsky, David M. Stern, and Shi-Fang Yan**

have invented certain new and useful improvements in

**Methods for Suppressing Early Growth Response - 1 Protein (Egr-1) to Reduce Vascular Injury In A  
Subject**

of which the following is a full, clear and exact description.

**Methods to Inhibit the Activity of Early Growth Response - 1**  
**Protein (Egr-1) To Reduce Vascular Injury In a Subject**

5 The invention disclosed herein was made with Government support under Grant No. HL 42507 from the National Institutes of Health of the U.S. Department of Health and Human Services. Accordingly, the U.S. Government has certain rights in this invention.

10 **Background of the Invention**

15 Throughout this application, various publications are referenced by author and date within the text. Full citations for these publications may be found listed alphabetically at the end of the specification immediately preceding the claims. All patents, patent applications and publications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety. The disclosures of these publications in their entireties are hereby  
20 incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein.

25 It has long been hypothesized that ischemia primes mechanisms leading to reperfusion injury and sets the stage for an exaggerated, maladaptive vascular response eventuating in tissue damage. Hypoxemia, a central component of the ischemic vascular milieu, has been defined as a key factor initiating vascular  
30 injury. To date, the cellular response to oxygen deprivation has largely been defined by studies of the transcription factor HIF (Hypoxia-Inducible Factor)-1. Activation of HIF-1 by hypoxia/hypoxemia facilitates metabolic adaptation to environmental challenge; glucose uptake by the noninsulin-dependent glucose





Summary of the Invention

The invention provides a method for reducing damage to an ischemic tissue which comprises contacting cells of the tissue with an inhibitor of Early Growth Response Factor - 1 Protein (Egr-1). In addition, the invention provides a method for reducing vascular injury during reperfusion of an ischemic tissue in a subject which comprises contacting the tissue with a compound which inhibits expression of Early Growth Response Factor - 1 (Egr-1) protein in the tissue so as to reduce vascular injury in the tissue during reperfusion. wherein the inhibitor is a nucleic acid consisting essentially of the polynucleotide sequence 5'- CTTGGCCGCTGCCAT-3' (SEQ ID NO:1). In one embodiment of the invention, the subject has suffered a stroke, or a myocardial infarction. In another embodiment of the invention, the subject is undergoing or has undergone angioplasty, cardiac surgery, vascular surgery, or organ transplantation.

### Brief Description of the Figures

Figures 1A, 1B1-B4, 1C1-C4, 1D, 1E1-E4, 1F1-F4. Ischemia/reperfusion induces tissue factor and PAI-1: effect of Egr-1. Mice underwent left lung I/R or no instrumentation (C=control), and lungs were harvested for Northern blotting (Figs. 1A, 1D), *in situ* hybridization (Figs. 1B1-B4, 1E1-E4), and immunohistochemical analysis (1C1-C4, 1F1-F4). Figs. 1A, 1B1-B4, 1C1-C4 Tissue factor. Total RNA was prepared from lung subjected to I/R and Northern blotting was performed (10  $\mu$ g/lane) with  $^{32}$ P-labelled cDNA probes for tissue factor (TF) and  $\beta$ -actin (Fig. 1A; upper panel). In the lower panel, densitometric analysis of three autoradiograms from three different experiments is shown, below the representative autoradiogram displayed in the upper panel. The intensity of the tissue factor mRNA band was normalized according to the intensity of the  $\beta$ -actin band in that lane. Other assays involving autoradiograms were similarly analyzed in the figures below. *In situ* hybridization (ISH) was performed with a digoxigenin-labelled riboprobe for tissue factor (Fig 1B1-B4) with tissue from wild-type mice: control lung (Fig. 1B-1) or I/R lung (Fig. 1B-2,3). Fig. 1B-4 shows F4/80 staining of a section adjacent to that shown in Fig 1B-3. Arrows denote cells in which TF mRNA and F4/80 immunoreactivity were colocalized (this same format is employed for all ISH figures below). Fig 1C1-C4. Immunostaining was performed with anti-tissue factor IgG using tissue from wild-type mice, control (Fig 1C-1) or I/R lung (Fig 1C-2), or Egr-1 null mice, control (Fig 1C-3) or I/R lung (Fig 1C-4). D-F. PAI-1. Northern blotting (Fig 1D), ISH (Fig 1E1-E4) and immunostaining (Fig 1F1-1F4) were performed to detect PAI-1 transcripts (Fig 1D, Fig 1E1-E3; E4 shows F4/80 staining of a section adjacent to that in E-3) and antigen (Fig. 1F1-F4). The origin of samples is the same as in A-C. \* indicates  $p < 0.01$  in panels Figs 1A, 1D. The bar in panels Figs 1B-1C and Figs 1E, 1F

indicates: 5  $\mu$ m (Fig 1B-1,2; 1C1-4; 1E-1,2; 1F1-4), and 2  $\mu$ m (1B-3,4; 1E-3,4). Results of representative experiments with =5 mice in each group are shown, and experiments were repeated three times. Beside each micrograph mouse genotype, with respect to Egr-1 (+/+ , wild-type and Egr-1 null), is indicated along with the experimental condition (control [C]=uninstrumented; I/R = ischemia/reperfusion).

Figures 2A, 2B1-2B4, 2C1-2C4. Ischemia/reperfusion induces VEGF.: effect of Egr-1- Mice underwent left lung I/R or no instrumentation (C=control), and lung was harvested for Northern blotting (Fig 2A), ISH (Figs 2B1-2B4), and immunohistochemistry [Figs 2C1-2C4] for VEGF. Northern blotting was performed on total RNA from control or I/R lung (10  $\mu$ g/lane) with 32P-labelled cDNA probes for VEGF and  $\beta$ -actin (Fig 2A). \* indicates  $p < 0.01$ . ISH was performed with a digoxigenin-labelled riboprobe for VEGF (Fig 2B1-2B4) with tissue from wild-type mice: control lung (Fig 2B-1) or I/R lung (Fig 2B-2,3). Fig 2B-4 shows F4/80 staining of a section adjacent to that shown in Fig 2B-3. Immunostaining was performed with anti-VEGF IgG using tissue from wild-type mice, control (Fig 2C-1) or I/R lung (Fig 2C-2), or from Egr-1 null mice, control (Fig 2C-3) or I/R lung (Fig 2C-4). The bar indicates 5  $\mu$ m (Fig 2B-1,2; Fig 2C1-4) and 2  $\mu$ m (Fig 2B-3,4). Results of representative experiments with =5 mice in each group are shown, and each experiment was repeated three times.

Figures 3A, 3B1-B4, 3C1-C4. Ischemia/reperfusion induces ICAM-1: effect of Egr-1. Mice underwent left lung I/R or no instrumentation (C=control), and lungs were harvested for Northern blotting (A), ISH (B) and immunohistochemistry (C) for ICAM-1. Northern blotting was performed on total RNA from control or I/R lung (10  $\mu$ g/lane) with 32P-labelled cDNA probes for ICAM-1 and  $\beta$ -actin (A). \* indicates  $p < 0.01$ . ISH was performed with a digoxigenin-labelled riboprobe for ICAM-1 and tissue from wild-type mice: control lung (B-1) or I/R lung (B-2,3). B-4 shows F4/80

staining of a section adjacent to that shown in B-3. Immunostaining was performed with anti-ICAM-1 IgG using tissue from wild-type mice, control (C-1) or I/R lung (C-2), or Egr-1 null mice, control (C-3) or I/R lung (C-4). The bar indicates 5  $\mu$ m (B-1,2; C-4) and 2  $\mu$ m (B-3,4). Results of representative experiments with =5 mice in each group are shown, and each experiment was repeated three times.

Figures 4A, 4B1-B4, 4C, 4D, 4E1-E4, 4F, 4G, 4H1-4H4, 4I, 4J, 4K, and 4L. Ischemia/reperfusion induces IL-1 $\beta$  and chemokines: effect of Egr-1. A-C. Expression of IL-1 $\beta$ . Mice underwent left lung I/R or no instrumentation (C=control), and lungs were harvested for Northern blotting (A), ISH (B) and ELISA [C] for IL-1 $\beta$ . Northern blotting was performed on total RNA from control or I/R lung (10  $\mu$ g/lane) with 32P-labelled cDNA probes for IL-1 $\beta$  and B-actin (A). ISH was performed with a digoxigenin-labelled riboprobe for IL-1 $\beta$  (B) with tissue from wild-type mice: control lung (B-1) or I/R lung (B-2,3). B-4 shows F4/80 staining of a section adjacent to that shown in B-3. In C, ELISA for IL-1 $\beta$  was performed on sera harvested after the 3 hr reperfusion period from wild-type or Egr-1 null mice subjected to I/R or from uninstrumented (C=control) mice. D-F. Expression of MIP-2 was determined by Northern analysis (D), ISH (E) and ELISA (F) as described for IL-1 $\beta$  except that MIP-2 cDNA/riboprobe and a MIP-2 ELISA were used. G-I. Expression of JE/MCP-1 was determined by Northern analysis (G), ISH (H) and ELISA (I) as described for IL-1 $\beta$  except that JE/MCP-1 cDNA/riboprobe and a JE/MCP-1 ELISA were used. J-K. Expression of IP-10 and RANTES mRNA. Northern analysis was performed on total RNA from control or I/R lung (10  $\mu$ g/lane) with 32P-labelled cDNA probes for IP-10 (J), RANTES (K) and B-actin (J,K). L. Expression of LT $\beta$ , MIF, and L32 mRNA. Ribonuclease protection assays were performed on RNA from control or I/R lung of wild-type or Egr-1 null mice to detect LT $\beta$ , MIF or L32. The bar indicates 5  $\mu$ m (panels 1-2 in B,E,H) and 2  $\mu$ m (panels 3-4 in B,E,H). Results of representative experiments with

=5 mice in each group are shown, and experiments were repeated three times. Beside each micrograph mouse genotype, with respect to Egr-1 (+/+, wild-type and -/-, Egr-1 null), is indicated along with the experimental condition (C [control]=uninstrumented; I/R = ischemia/reperfusion). indicates  $p < 0.01$ .

Figures 5A, 5B1-5B4, 5C, 5D, 5E1-5E2, 5F, 5G and 5H. Ischemia/reperfusion induces and activates Egr-1 in murine lung. Wild-type mice underwent left lung ischemia for the indicated time or the full protocol of I/R, or no instrumentation (control), and lungs were harvested. Northern blotting was performed on total RNA from control or I/R lung (10  $\mu$ g/lane) with  $^{32}$ P-labelled cDNA probes for Egr-1 and B-actin (A). ISH was performed with a digoxigenin-labelled riboprobe for Egr-1 (B) using tissue from wild-type mice: control (B-1) or LIR lung (B-2,3). B-4 shows F4/80 staining of a section adjacent to that shown in B-3. C. Inunoblotting was performed using nuclear extracts from control or I/R lung of wild type mice (10  $\mu$ g protein/lane) with anti-Egr-1 IgG (lanes 1-5) or anti-Sp1 IgG (lanes 6-10). Migration of simultaneously run molecular weight standards is shown on the far left of each gel. In D, analysis of data similar to that displayed in C (3 representative experiments) is shown. E. Immunostaining was performed with anti-Egr-1 IgG using tissue from wild-type mice, control lung (E-1) or I/R lung (E-2). F. EMSA was performed using  $^{32}$ P-labelled Egr probe and nuclear extract (NE; 10  $\mu$ g protein/lane) from wild-type mice, either control or I/R lung. Where indicated, 100-fold excess unlabelled (cold) Egr or Sp1 probe was added to nuclear extracts, or anti-Egr-1 IgG or nonimmune IgG (2  $\mu$ g/ml in each case) was added to extracts from I/R lung. Lanes indicate: 1, free probe; 2, nuclear extract from uninstrumented (control) mice; 3-5, nuclear extracts from lung subjected to 15, 30 and 60 min of ischemia; 6, nuclear extract from lung subject to I/R; 7,8, nuclear extracts identical to those in 5

(60 min ischemia) and 6 (I/R), respectively, incubated with anti-Egr-1 IgG (aEgr-1); 9-10, nuclear extracts as in 5-6, respectively, but excess unlabelled (cold) Sp1 probe added during the incubation period; 11-12, nuclear extracts identical to those in 5-6, respectively, with excess unlabelled (cold) Egr probe; and, 13-14, same as 7-8, but nonimmune (NI) IgG was used in place of anti-Egr-1 IgG. G. EMSA with <sup>32</sup>P-labelled Sp I probe and the indicated nuclear extracts. In H, analysis of data similar to that shown in panels F-G (three representative experiments) is shown. The bar indicates 5  $\mu$ m (B-1,2; D-1,2) and 2  $\mu$ m (B-3,4). \*p<0.01 and \*\*p<0.05.

Figures 6A, 6B, 6C, 6D, and 6E. Murine model of lung ischemia/reperfusion: effect of Egr-1. Mice were subjected to the left lung I (ischemia; 1 hr)/R (reperfusion; 3 hr) protocol as described in the text, blood flow to the uninstrumented right lung was blocked, and mortality was determined after 30 min with only the left lung in the circulation (A). In other experiments, arterial oxygenation was determined after I/R and the 30 min observation period (B). In panel C, after the indicated period of ischemia or I/R, animals received systemic heparin and the ischemic lung was processed for detection of fibrin by immunoblotting. In panels D-E, after I/R, myeloperoxidase activity (D) and the ratio of wet/dry lung weight (E) in the ischemic lung were determined. In B-E, N=5 for each group. +/+ refers to wild-type genotype for Egr-1 and -/- refers to homozygous Egr-1 null mice. Results of representative experiments are shown, and each experiment was repeated three times.

Figures 7A, 7B. Hypoxia induces Egr-1-dependent expression of mRNA for IL-1 $\beta$ , MIP-2, and JE/MCP-1, whereas expression of transcripts for LT $\beta$ , MIF, IL-7 and L32 remain unchanged. Mice were exposed to hypoxia (H) or the ambient atmosphere (N= normoxia), and total RNA

was isolated from the lung and subjected to ribonuclease protection assay to detect transcripts for EL-1 $\beta$ , IL-7, MIP-2, JE/MCP-1. MIF, LT $\beta$  and L32. Results of representative experiments with =5 mice in each group are shown, and each experiment was repeated three times.  
5 \*p<0.01.

Figure 8. Northern Blotting; Egr-1/b-actin. Northern blotting of Egr-1 in untreated rat lung tissue, preserved but not transplanted lung tissue, and lung tissue following preservation /transplantation and reperfusion. Data are normalized to beta  
10 actin for control.

Figure 9. Western Blotting; EGR-1. Western blotting of Egr-1 in untreated rat lung tissue, preserved but not transplanted lung  
15 tissue, and lung tissue following preservation /transplantation and reperfusion.

Figure 10. Northern Blotting; Egr-1/b-actin. Effect of cationic liposomal carrier (control), scrambled sequence Egr-1  
20 oligodeoxyribonucleotide, or antisense Egr-1 oligodeoxyribonucleotide on Egr-1 mRNA expression after lung transplantation. Fresh denotes nontransplanted lung tissue. Data are normalized to beta actin for control.

Figure 11. Western Blotting; EGR-1. Effect of cationic liposomal carrier (control), scrambled sequence Egr-1  
25 oligodeoxyribonucleotide, or antisense Egr-1 oligodeoxyribonucleotide on Egr-1 protein expression after lung transplantation. Fresh denotes nontransplanted lung tissue.

Figure 12. Effect of control (carrier) or Egr-I antisense oligodeoxyribonucleotide on gas exchange following left lung  
30 transplantation and circulatory exclusion of the right



(nontransplanted) lung.

Figure 13. Survival Rate. Effect of control (carrier) or Egr- 1  
antisense oligodeoxyribonucleotide on recipient survival following  
5 left lung transplantation and circulatory exclusion of the right  
(nontransplanted) lung.

0054330" 68221360

**Detailed Description of the Invention**

The present invention provides a method for reducing damage to an ischemic tissue which comprises contacting cells of the tissue with an inhibitor of Early Growth Response Factor - 1 Protein (Egr-1).

In one embodiment of the invention, the inhibitor is an organic molecule having a molecular weight from about 500 daltons to about 50 kilodaltons. In another embodiment, the inhibitor is a nucleic acid. In another embodiment of the invention, the inhibitor is a compound which inhibits activity of Early Growth Response Factor - 1 Protein (Egr-1) conjugated to a carrier.

In one embodiment of the invention, the inhibitor is a compound which inhibits expression of the Early Growth Response Factor - 1 Protein (Egr-1) in the cells of the tissue. In another embodiment, the inhibitor is a nucleic acid molecule which comprises a polynucleotide sequence complementary to the polynucleotide sequence of Early Growth Response Factor - 1 mRNA.

In another embodiment of the invention, the inhibitor is a peptide, a peptidomimetic compound, a nucleic acid molecule, a small molecule, an organic compound, an inorganic compound, or an antibody or a fragment thereof. In another embodiment of the invention, the carrier is a pharmaceutically acceptable carrier.

In another embodiment of the invention, the tissue is vascular tissue. In another embodiment of the invention, the tissue is a lung, a heart, a kidney, a vein, an artery, a stomach, a colon, a liver, skin, an eye, a pancreas, a finger, a brain, a toe or a limb. In another embodiment of the invention, the contacting of the cells with the inhibitor occurs *in vitro*. In another embodiment of the invention, the ischemic tissue is to be

transplanted into a subject. In another embodiment of the invention, the tissue has been subjected to reduced or interrupted blood flow. In another embodiment of the invention, the damage to the ischemic tissue comprises cell death, abnormal cell function, abnormal cell growth, or inability for cell to maintain normal function. In another embodiment of the invention, the inhibitor is a nucleic acid consisting essentially of the polynucleotide sequence 5'- CTTGGCCGCTGCCAT-3' (SEQ ID NO:1).

The present invention also provides for a method for reducing vascular injury during reperfusion of an ischemic tissue in a subject which comprises contacting the tissue with a compound which inhibits expression of Early Growth Response Factor - 1 (Egr-1) protein in the tissue so as to reduce vascular injury in the tissue during reperfusion.

In one embodiment of the invention, the tissue is an ischemic tissue. In another embodiment of the invention, the tissue is an organ which is to be transplanted into the subject. In another embodiment of the invention, the tissue is a lung, a heart, a kidney, a vein, an artery, a stomach, a colon, a liver, skin, an eye, a pancreas, a brain, a finger, a toe or a limb. In another embodiment of the invention, the compound is a nucleic acid which comprises a polynucleotide sequence complementary to the polynucleotide sequence of Early Growth Response Factor - 1 mRNA.

In another embodiment of the invention, the compound is a peptide, a peptidomimetic compound, a nucleic acid molecule, a small molecule, an organic compound, an inorganic compound, or an antibody or a fragment thereof. In another embodiment of the invention, the subject has suffered a stroke, or a myocardial infarction. In another embodiment of the invention, the subject is undergoing angioplasty, cardiac surgery, vascular surgery, or organ

transplantation. In another embodiment of the invention, the vascular surgery is coronary artery surgery. In another embodiment of the invention, the vascular injury comprises cell death, abnormal cell function, abnormal cell growth, or inability for cell to maintain normal function.

In another embodiment of the invention, the inhibitor is a nucleic acid consisting essentially of the polynucleotide sequence 5'-CTTGCCGCTGCCAT-3' (SEQ ID NO:1). In another embodiment of the invention, the inhibitor is contacted with the tissue before, during or after reperfusion of the ischemic tissue.

In one embodiment of the present invention, the tissue is from a subject which is suffering from an ischemic disorder. In another embodiment of the invention, the ischemic disorder comprises a peripheral vascular disorder, a pulmonary embolus, a venous thrombosis, a myocardial infarction, a transient ischemic attack, unstable angina, a reversible ischemic neurological deficit, sickle cell anemia or a stroke disorder.

In another embodiment, the ischemic disorder is iatrogenically induced. In another embodiment, the subject is undergoing angioplasty, heart surgery, lung surgery, spinal surgery, brain surgery, vascular surgery, abdominal surgery, or organ transplantation surgery. In another embodiment, the organ transplantation surgery comprises heart, lung, pancreas or liver transplantation surgery.

In one embodiment of the invention, the inhibitor is administered to the subject, or contacted with the tissue over a period of time in order to inhibit the activity of Egr-1 protein in the cells of the tissue.

In another embodiment, the period of time comprises from about 5 days before surgery or onset of the disorder to about 5 days after surgery or the onset of the disorder. In another embodiment, the period of time comprises from about 1 hour before surgery or the onset of the disorder to about 12 hours after surgery or the onset of the disorder. In another embodiment, the period of time comprises from about 12 hours before surgery or the onset of the disorder to about 1 hour after surgery or the onset of the disorder. In another embodiment, the period of time comprises from about 1 hour before surgery or the onset of the disorder to about 1 hour after surgery or the onset of the disorder.

As used herein, the "ischemic disorder" encompasses and is not limited to a peripheral vascular disorder, a venous thrombosis, a pulmonary embolus, a myocardial infarction, a transient ischemic attack, lung ischemia, unstable angina, a reversible ischemic neurological deficit, adjunct thromolytic activity, excessive clotting conditions, reperfusion injury, sickle cell anemia, a stroke disorder or an iatrogenically induced ischemic period such as angioplasty.

In one embodiment of the present invention, the subject is undergoing heart surgery, angioplasty, lung surgery, spinal surgery, brain surgery, vascular surgery, abdominal surgery, or organ transplantation surgery. The organ transplantation surgery may include heart, lung, pancreas or liver transplantation surgery.

The tissue referred to herein is made up of cells. The cell may be a eukaryotic cell. The cell may be a cell of a subject. The subject may be a human. The cell may be a neuronal cell, an endothelial cell, a glial cell, a microglial cell, a smooth muscle cell, a somatic cell, a bone marrow cell, a liver cell, an intestinal cell, a germ cell, a myocyte, a mononuclear phagocyte,

an endothelial cell, a tumor cell, a lymphocyte cell, a mesangial cell, a retinal epithelial cell, a retinal vascular cell a ganglion cell or a stem cell. The cell may also be other kinds of cells not explicitly listed herein. The cell may be any human cell. The cell may be a normal cell, an activated cell, a neoplastic cell, a diseased cell or an infected cell.

In one embodiment, the inhibitor comprises a peptide, a peptidomimetic compound, a nucleic acid molecule, a small molecule, an organic compound, an inorganic compound, or an antibody or a fragment thereof. The inhibitor may be an isolated peptide having an amino acid sequence which is a fragment of the complete Egr-1 amino acid sequence and so that the fragment works as a competitive inhibitor of the naturally occurring Egr-1 protein. The inhibitor may be any of the compounds or compositions described herein.

The inhibitor may be an antisense nucleic acid molecule which has a sequence which is the complement of the mRNA sequence of Egr-1. The inhibitor may be an antisense nucleic acid which is of a length from about 9 nucleotides long (i.e., a polynucleotide consisting of 9 bases) to about 35 nucleotides (i.e. a polynucleotide consisting of 35 bases) long. The nucleic acid could also be of a much longer length. The length of an antisense nucleic acid molecule is generally shorter than an average coding sequence. If, however, the inhibitor is a nucleic acid which does not work as an antisense molecule, than the length, of course, would be much longer.

The inhibitor could also be a chimeric nucleic acid which comprises at least a portion of the Egr-1 coding sequence linked in frame to a nucleic acid which encodes a targeting protein (i.e., a protein which can specifically move to and bind to a particular location in the cell).

In another embodiment of the invention, the inhibitor is a mutein (i.e., a mutated Egr-1 protein). This mutein would include changes, additions, deletions, substitutions to the normally occurring Egr-1 amino acid sequence so that the resultant mutein would lack the activity of a normal Egr-1 protein. This mutein would retain activity which is required to maintain its ability to act as a competitive inhibitor. For example, one such mutein may retain the ability to bind but lack an enzymatic activity.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, virology, recombinant DNA technology, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989); DNA Cloning, Vols. I and II (D. N. Glover ed. 1985); Oligonucleotide Synthesis (M. J. Gait ed. 1984); Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984); Animal Cell Culture (R. K. Freshney ed. 1986); Immobilized Cells and Enzymes (IRL press, 1986); Perbal, B., A Practical Guide to Molecular Cloning (1984); the series, Methods In Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.); and Handbook of Experimental Immunology, Vols. I-IV (D. M. Weir and C. C. Blackwell eds., 1986, Blackwell Scientific Publications).

As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural references unless the content clearly dictates otherwise.

In another embodiment of the invention, the "introducing" is carried out by a means selected from the group consisting of adenovirus infection, liposome-mediated transfer, topical application to the

cell, and microinjection.

In another embodiment of the invention, the administering is carried out via injection, oral administration, or topical administration.

In another embodiment of the invention, the carrier is an aqueous carrier, a liposome, or a lipid carrier.

The present invention provides a pharmaceutical composition which comprises an effective amount of an inhibitor of Egr-1 protein and a pharmaceutically acceptable carrier. In one embodiment, the carrier comprises a diluent. In another embodiment, the carrier comprises an appropriate adjuvant, a herpes virus, a liposome, a microencapsule, a polymer encapsulated cell or a retroviral vector. In another embodiment, the carrier is an aerosol, intravenous, oral or topical carrier.

In one embodiment, the inhibitor of the invention inhibits Egr-1 protein activity. In another embodiment, the inhibitor inhibits mRNA translation, DNA transcription or initiation of DNA transcription.

One embodiment of the present invention is a peptidomimetic compound which is an inhibitor of Egr-1 protein activity or inhibitor of Egr-1 expression, wherein the compound has a bond, a peptide backbone or an amino acid component replaced with a suitable mimic. Examples of unnatural amino acids which may be suitable amino acid mimics include  $\beta$ -alanine, L- $\alpha$ -amino butyric acid, L- $\gamma$ -amino butyric acid, L- $\alpha$ -amino isobutyric acid, L- $\epsilon$ -amino caproic acid, 7-amino heptanoic acid, L-aspartic acid, L-glutamic acid, cysteine (acetamindomethyl), N- $\epsilon$ -Boc-N- $\alpha$ -CBZ-L-lysine, N- $\epsilon$ -Boc-N- $\alpha$ -Fmoc-L-lysine, L-methionine sulfone, L-norleucine, L-



norvaline, N- $\alpha$ -Boc-N- $\delta$ CBZ-L-ornithine, N- $\delta$ -Boc-N- $\alpha$ -CBZ-L-ornithine, Boc-p-nitro-L-phenylalanine, Boc-hydroxyproline, Boc-L-thioprolin. (Blondelle, et al. 1994; Pinilla, et al. 1995).

5 Also provided by the invention are pharmaceutical compositions comprising therapeutically effective amounts of polypeptide products of the invention together with suitable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers. An "effective amount" as used herein refers to that  
10 amount which provides a therapeutic effect for a given condition and administration regimen. Such compositions are liquids or lyophilized or otherwise dried formulations and include diluents of various buffer content (e.g., Tris-HCl., acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent  
15 absorption to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts), solubilizing agents (e.g., glycerol, polyethylene glycerol), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimerosal, benzyl alcohol, parabens), bulking substances or tonicity modifiers  
20 (e.g., lactose, mannitol), covalent attachment of polymers such as polyethylene glycol to the protein, complexation with metal ions, or incorporation of the material into or onto particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, hydrogels, etc, or onto liposomes,  
25 microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts. Such compositions will influence the physical state, solubility, stability, rate of *in vivo* release, and rate of *in vivo* clearance. The choice of compositions will depend on the physical and chemical properties of  
30 the protein having the activity of a Factor IXa compound. For example, a product which includes a controlled or sustained release composition may include formulation in lipophilic depots (e.g., fatty acids, waxes, oils). Also comprehended by the invention are

particulate compositions coated with polymers (e.g., poloxamers or poloxamines) and the compound coupled to antibodies directed against tissue-specific receptors, ligands or antigens or coupled to ligands of tissue-specific receptors. Other embodiments of the compositions of the invention incorporate particulate forms protective coatings, protease inhibitors or permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal, oral, injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial or intralesional.

The present invention incorporates U.S. Patent Nos. 5,446,128, 5,422,426 and 5,440,013 in their entireties as references which disclose the synthesis of peptidomimetic compounds and methods related thereto. The compounds of the present invention may be synthesized using these methods. The present invention provides for peptidomimetic compounds which have substantially the same three-dimensional structure as those compounds described herein.

In addition to the compounds disclosed herein having naturally-occurring amino acids with peptide or unnatural linkages, the present invention also provides for other structurally similar compounds such as polypeptide analogs with unnatural amino acids in the compound. Such compounds may be readily synthesized on a peptide synthesizer available from vendors such as Applied Biosystems, Dupont and Millipore.

As used herein, the term "pharmaceutically acceptable carrier" encompasses any of the standard pharmaceutically accepted carriers, such as phosphate buffered saline solution, water, emulsions such as an oil/water emulsion or a triglyceride emulsion, various types of wetting agents, tablets, coated tablets and capsules. An example of an acceptable triglyceride emulsion useful in intravenous and

intraperitoneal administration of the compounds is the triglyceride emulsion commercially known as Intralipid®.

Typically such carriers contain excipients such as starch, milk, sugar, certain types of clay, gelatin, stearic acid, talc, vegetable fats or oils, gums, glycols, or other known excipients. Such carriers may also include flavor and color additives or other ingredients.

When administered, compounds are often cleared rapidly from the circulation and may therefore elicit relatively short-lived pharmacological activity. Consequently, frequent injections of relatively large doses of bioactive compounds may be required to sustain therapeutic efficacy. Compounds modified by the covalent attachment of water-soluble polymers such as polyethylene glycol, copolymers of polyethylene glycol and polypropylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone or polyproline are known to exhibit substantially longer half-lives in blood following intravenous injection than do the corresponding unmodified compounds (Abuchowski et al., 1981; Newmark et al., 1982; and Katre et al., 1987). Such modifications may also increase the compound's solubility in aqueous solution, eliminate aggregation, enhance the physical and chemical stability of the compound, and greatly reduce the immunogenicity and reactivity of the compound. As a result, the desired *in vivo* biological activity may be achieved by the administration of such polymer-compound adducts less frequently or in lower doses than with the unmodified compound.

Attachment of polyethylene glycol (PEG) to compounds is particularly useful because PEG has very low toxicity in mammals (Carpenter et al., 1971). For example, a PEG adduct of adenosine deaminase was approved in the United States for use in humans for

the treatment of severe combined immunodeficiency syndrome. A second advantage afforded by the conjugation of PEG is that of effectively reducing the immunogenicity and antigenicity of heterologous compounds. For example, a PEG adduct of a human protein might be useful for the treatment of disease in other mammalian species without the risk of triggering a severe immune response. The compound of the present invention capable of alleviating symptoms of a cognitive disorder of memory or learning may be delivered in a microencapsulation device so as to reduce or prevent an host immune response against the compound or against cells which may produce the compound. The compound of the present invention may also be delivered microencapsulated in a membrane, such as a liposome.

Polymers such as PEG may be conveniently attached to one or more reactive amino acid residues in a protein such as the alpha-amino group of the amino terminal amino acid, the epsilon amino groups of lysine side chains, the sulfhydryl groups of cysteine side chains, the carboxyl groups of aspartyl and glutamyl side chains, the alpha-carboxyl group of the carboxy-terminal amino acid, tyrosine side chains, or to activated derivatives of glycosyl chains attached to certain asparagine, serine or threonine residues.

Numerous activated forms of PEG suitable for direct reaction with proteins have been described. Useful PEG reagents for reaction with protein amino groups include active esters of carboxylic acid or carbonate derivatives, particularly those in which the leaving groups are N-hydroxysuccinimide, p-nitrophenol, imidazole or 1-hydroxy-2-nitrobenzene-4-sulfonate. PEG derivatives containing maleimido or haloacetyl groups are useful reagents for the modification of protein free sulfhydryl groups. Likewise, PEG reagents containing amino hydrazine or hydrazide groups are useful for reaction with aldehydes generated by periodate oxidation of

carbohydrate groups in proteins.

### Definitions

5 As used herein "nucleic acid molecule" includes both DNA and RNA and, unless otherwise specified, includes both double-stranded and single-stranded nucleic acids. Also included are hybrids such as DNA-RNA hybrids. Reference to a nucleic acid sequence can also  
10 include modified bases as long as the modification does not significantly interfere either with binding of a ligand such as a protein by the nucleic acid or Watson-Crick base pairing.

Two DNA or polypeptide sequences are "substantially homologous" when at least about 80% (preferably at least about 90%, and most  
15 preferably at least about 95%) of the nucleotides or amino acids match over a defined length of the molecule. As used herein, "substantially homologous" also refers to sequences showing identity to the specified DNA or polypeptide sequence. DNA sequences that are substantially homologous can be identified in a Southern hybridization, experiment under, for example, stringent conditions,  
20 as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Sambrook et al., supra; DNA Cloning, vols I & II, supra; Nucleic Acid Hybridization, supra.

25 A DNA "coding sequence" or a "nucleotide sequence encoding" a particular protein, is a DNA sequence which is transcribed and translated into a polypeptide *in vivo* or *in vitro* when placed under the control of appropriate regulatory sequences. The boundaries of  
30 the coding sequence are determined by a start codon at the 5'-(amino) terminus and a translation stop codon at the 3'-(carboxy) terminus. A coding sequence can include, but is not limited to, procaryotic sequences, cDNA from eucaryotic mRNA, genomic DNA

sequences from eucaryotic (e.g., mammalian) sources, viral RNA or DNA, and even synthetic nucleotide sequences. A transcription termination sequence will usually be located 3' to the coding sequence.

5 DNA "control sequences" refers collectively to promoter sequences, polyadenylation signals, transcription termination sequences, upstream regulatory domains, enhancers, and the like, untranslated regions, including 5'-UTRs and 3'-UTRs, which collectively provide  
10 for the transcription and translation of a coding sequence in a host cell.

005280 6824650  
15 "Operably linked" refers to an arrangement of nucleotide sequence elements wherein the components so described are configured so as to perform their usual function. Thus, control sequences operably linked to a coding sequence are capable of effecting the expression of the coding sequence. The control sequences need not be contiguous with the coding sequence, so long as they function to direct the expression thereof. Thus, for example, intervening  
20 untranslated yet transcribed sequences can be present between a promoter sequence and the coding sequence and the promoter sequence can still be considered "operably linked" to the coding sequence. A cell has been "transformed" by exogenous DNA when such exogenous DNA has been introduced inside the cell membrane. Exogenous DNA  
25 may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell. In procaryotes and yeasts, for example, the exogenous DNA may be maintained on an episomal element, such as a plasmid. In eucaryotic cells, a stably transformed cell is generally one in which the exogenous DNA has  
30 become integrated into the chromosome so that it is inherited by daughter cells through chromosome replication, or one which includes stably maintained extrachromosomal plasmids. This stability is demonstrated by the ability of the eucaryotic cell to

establish cell lines or clones comprised of a population of daughter cells containing the exogenous DNA.

5 A "heterologous" region of a DNA construct is an identifiable segment of DNA within or attached to another DNA molecule that is not found in association with the other molecule in nature. One example of a heterologous coding sequence is a construct where the coding sequence itself is not found in nature (e.g., synthetic sequences having codons different from the native gene). Likewise,  
10 a chimeric sequence, comprising a heterologous structural gene and a gene encoding an Egr-1 protein or a portion of an Egr-1 protein, linked to a endothelial cell specific promoter will be considered heterologous since such chimeric constructs are not normally found in nature. Allelic variation or naturally occurring mutational  
15 events do not give rise to a heterologous region of DNA, as used herein.

#### Vectors

Especially preferred are virus based vectors. In the case of  
20 eukaryotic cells, retrovirus or adenovirus based vectors are preferred. Such vectors contain all or a part of a viral genome, such as long term repeats ("LTRs"), promoters (e.g., CMV promoters, SV40 promoter, RSV promoter), enhancers, and so forth. When the host cell is a prokaryote, bacterial viruses, or phages, are  
25 preferred. Exemplary of such vectors are vectors based upon, e.g., lambda phage. In any case, the vector may comprise elements of more than one virus.

30 The resulting vectors are transfected or transformed into a host cell, which may be eukaryotic or prokaryotic. The gene transfer vector of the present invention may additionally comprise a gene encoding a marker or reporter molecule to more easily trace

expression of the vector.

The invention provides for a gene transfer vector which comprises a nucleic acid which encodes a Egr-1 protein. The gene transfer vector may contain more than one gene encoding the same or different foreign polypeptides or RNAs. The gene transfer vector may be any construct which is able to replicate within a host cell and includes plasmids, DNA viruses, retroviruses, as well as isolated nucleotide molecules. Liposome-mediated transfer of the gene transfer vector may also be carried out in the present invention. Examples of such plasmids which can be employed in the present invention include pGL3-based plasmids (Promega). An example of such DNA viruses which can be employed in the present invention are adenoviruses. Adenoviruses have attracted increasing attention as expression vectors, especially for human gene therapy (Berkner, Curr. Top. Microbiol. Immunol., 158:39-66 (1992)).

Examples of such adenovirus serotypes which can be employed in the present invention are well-known in the art and include more than 40 different human adenoviruses, e.g., Ad12 (subgenus A), Ad3 and Ad7 (Subgenus B), Ad2 and Ad5 (Subgenus C), Ad8 (Subgenus D), Ad4 (Subgenus E), Ad40 (Subgenus F) (Wigand et al, In: Adenovirus DNA, Doerfler, Ed., Martinus Nijhoff Publishing, Boston, pp. 408-441 (1986)). Ad5 of subgroup C is the preferred adenovirus employed in the present invention. This is because Ad5 is a human adenovirus about which a great deal of biochemical and genetic information is known, and it has historically been used for most constructions employing adenovirus as a vector. Also, adenoviral vectors are commercially available, e.g., pCA3 (Microbix Biosystems Inc.).

Methods for producing adenovirus vectors are well-known in the art (Berkner et al, Nucleic Acids Res., 11:6003-6020 (1983); van Doren et al, Mol. Cell. Biol., 4:1653-1656 (1984); Ghosh-Choudhury et al, Biochem. Biophys. Res. Commun., 147:964-973 (1987); McGrory et al,



Virol., 163:614-617 (1988); and Gluzman et al, In: Eukaryotic Viral Vectors, Ed. Gluzman, Y. pages 187-192, Cold Spring Harbor Laboratory (1982)).

5 Preferred vectors for use in the methods of the present invention are viral including adenoviruses, retroviral, vectors, adeno-associated viral (AAV) vectors.

10 The viral vector selected should meet the following criteria: 1) the vector must be able to infect cells of an ischemic tissue of a subject (wherein the subject can be a human in one embodiment) and thus viral vectors having an appropriate host range must be selected; 2) the transferred gene should be capable of persisting and being expressed in a cell for an extended period of time; and  
15 3) the vector should be safe to the host and cause minimal cell transformation. Retroviral vectors and adenoviruses offer an efficient, useful, and presently the best-characterized means of introducing and expressing foreign genes efficiently in mammalian cells. These vectors have very broad host and cell type ranges,  
20 express genes stably and efficiently. The safety of these vectors has been proved by many research groups. In fact many are in clinical trials.

25 Other virus vectors that may be used for gene transfer into cells for correction of disorders include retroviruses such as Moloney murine leukemia virus (MoMuLV); papovaviruses such as JC, SV40, polyoma, adenoviruses; Epstein-Barr Virus (EBV); papilloma viruses, e.g. bovine papilloma virus type I (BPV); vaccinia and poliovirus and other human and animal viruses.

30 Adenoviruses have several properties that make them attractive as cloning vehicles (Bachettis et al.: Transfer of gene for thymidine kinase-deficient human cells by purified herpes simplex viral DNA.

PNAS USA, 1977 74:1590; Berkner, K. L.: Development of adenovirus vectors for expression of heterologous genes. Biotechniques, 1988 6:616; Ghosh-Choudhury G., et al., Human adenovirus cloning vectors based on infectious bacterial plasmids. Gene 1986; 50:161; Hag-Ahmand Y., et al., Development of a helper-independent human adenovirus vector and its use in the transfer of the herpes simplex virus thymidine kinase gene. J Virol 1986; 57:257; Rosenfeld M., et al., Adenovirus-mediated transfer of a recombinant .alpha..sub.1 - antitrypsin gene to the lung epithelium in vivo. Science 1991; 252:431).

For example, adenoviruses possess an intermediate sized genome that replicates in cellular nuclei; many serotypes are clinically innocuous; adenovirus genomes appear to be stable despite insertion of foreign genes; foreign genes appear to be maintained without loss or rearrangement; and adenoviruses can be used as high level transient expression vectors with an expression period up to 4 weeks to several months. Extensive biochemical and genetic studies suggest that it is possible to substitute up to 7-7.5 kb of heterologous sequences for native adenovirus sequences generating viable, conditional, helper-independent vectors (Kaufman R. J.; identification of the component necessary for adenovirus translational control and their utilization in cDNA expression vectors. PNAS USA, 1985 82:689).

AAV is a small human parvovirus with a single stranded DNA genome of approximately 5 kb. This virus can be propagated as an integrated provirus in several human cell types. AAV vectors have several advantage for human gene therapy. For example, they are trophic for human cells but can also infect other mammalian cells; (2) no disease has been associated with AAV in humans or other animals; (3) integrated AAV genomes appear stable in their host cells; (4) there is no evidence that integration of AAV alters

expression of host genes or promoters or promotes their rearrangement; (5) introduced genes can be rescued from the host cell by infection with a helper virus such as adenovirus.

5 HSV-1 vector system facilitates introduction of virtually any gene into non-mitotic cells (Geller et al. an efficient deletion mutant packaging system for a defective herpes simplex virus vectors: Potential applications to human gene therapy and neuronal physiology. PNAS USA, 1990 87:8950).

10 Another vector for mammalian gene transfer is the bovine papilloma virus-based vector (Sarver N, et al., Bovine papilloma virus DNA: A novel eukaryotic cloning vector. Mol Cell Biol 1981; 1:486).

15 Vaccinia and other poxvirus-based vectors provide a mammalian gene transfer system. Vaccinia virus is a large double-stranded DNA virus of 120 kilodaltons (kd) genomic size (Panicali D, et al., Construction of poxvirus as cloning vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccine virus. Proc Natl Acad Sci USA 1982; 79:4927; Smith et al. infectious vaccinia virus recombinants that express hepatitis B virus surface antigens. Nature, 1983 302:490.)

25 Retroviruses are packages designed to insert viral genes into host cells (Guild B, et al., Development of retrovirus vectors useful for expressing genes in cultured murine embryonic cells and hematopoietic cells in vivo. J Virol 1988; 62:795; Hock R. A., et al., Retrovirus mediated transfer and expression of drug resistance genes in human hemopoietic progenitor cells. Nature 1986; 320:275).

30 The basic retrovirus consists of two identical strands of RNA packaged in a proviral protein. The core surrounded by a protective coat called the envelope, which is derived from the membrane of the

previous host but modified with glycoproteins contributed by the virus.

Markers and amplifiers can also be employed in the subject expression systems. A variety of markers are known which are useful in selecting for transformed cell lines and generally comprise a gene whose expression confers a selectable phenotype on transformed cells when the cells are grown in an appropriate selective medium. Such markers for mammalian cell lines include, for example, the bacterial xanthine-guanine phosphoribosyl transferase gene, which can be selected for in medium containing mycophenolic acid and xanthine (Mulligan et al. (1981) Proc. Natl. Acad. Sci. USA 78:2072-2076), and the aminoglycoside phosphotransferase gene (specifying a protein that inactivates the antibacterial action of neomycin/kanamycin derivatives), which can be selected for using medium containing neomycin derivatives such as G418 which are normally toxic to mammalian cells (Colbere-Garapin et al. (1981) J. Mol. Biol. 150:1-14). Useful markers for other eucaryotic expression systems, are well known to those of skill in the art.

Infection can be carried out *in vitro* or *in vivo*. *In vitro* infection of cells is performed by adding the gene transfer vectors to the cell culture medium. When infection is carried out *in vivo*, the solution containing the gene transfer vectors may be administered by a variety of modes, depending on the tissue which is to be infected. Examples of such modes of administration include injection of gene transfer vectors into the skin, topical application onto the skin, direct application to a surface of epithelium, or instillation into an organ (e.g., time release patch or capsule below the skin or into a tumor). Expression can be amplified by placing an amplifiable gene, such as the mouse dihydrofolate reductase (dhfr) gene adjacent to the coding sequence. Cells can then be selected for methotrexate resistance

in dhfr-deficient cells. See, e.g. Urlaub et al. (1980) Proc. Natl. Acad. Sci. USA 77:4216-4220; Rungold et al. (1981) J. Mol. and Appl. Genet. 1:165-175.

5 The above-described system can be used to direct the expression of a wide variety of procaryotic, eucaryotic and viral proteins, including, for example, viral glycoproteins suitable for use as vaccine antigens, immunomodulators for regulation of the immune response, hormones, cytokines and growth factors, as well as  
10 proteins useful in the production of other biopharmaceuticals.

It may also be desirable to produce mutants or analogs of the proteins of interest, such as the Egr-1 protein. Such a mutant or analog provided by the present invention would have the ability to  
15 act as a competitive inhibitor of the Egr-1 protein itself. Mutants or analogs may be prepared by the deletion of a portion of the sequence encoding the protein, by insertion of a sequence, and/or by substitution of one or more nucleotides within the sequence. Techniques for modifying nucleotide sequences, such as  
20 site-directed mutagenesis, are well known to those skilled in the art. See, e.g., Sambrook et al., supra; DNA Cloning, Vols. I and II, supra; Nucleic Acid Hybridization, supra.

The transformation procedure used depends upon the host to be transformed. Mammalian cells can conveniently be transformed using,  
25 for example, DEAE-dextran based procedures, calcium phosphate precipitation (Graham, F. L. and Van der Eb, A. J. (1973) Virology 52:456-467), protoplast fusion, liposome-mediated transfer, polybrene-mediated transfection and direct microinjection of the DNA into nuclei. Bacterial cells will generally be transformed  
30 using calcium chloride, either alone or in combination with other divalent cations and DMSO (Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989)). DNA can also

be introduced into bacterial cells by electroporation. Methods of introducing exogenous DNA into yeast hosts typically include either the transformation of spheroplasts or transformation of intact yeast cells treated with alkali cations.

5 The constructs can also be used in gene therapy or nucleic acid immunization, to direct the production of the desired gene product in vivo, by administering the expression constructs directly to a subject for the *in vivo* translation thereof. See, e.g. EPA  
10 Publication No. 336,523 (Dreano et al., published Oct. 11, 1989). Alternatively, gene transfer can be accomplished by transfecting the subject's cells or tissues with the expression constructs *ex vivo* and reintroducing the transformed material into the host. The constructs can be directly introduced into the host organism, i.e.,  
15 by injection (see International Publication No. WO/90/11092; and Wolff et al., (1990) Science 247:1465-1468). Liposome-mediated gene transfer can also be accomplished using known methods. See, e.g., Hazinski et al., (1991) Am. J. Respir. Cell Mol. Biol. 4:206-209; Brigham et al. (1989) Am. J. Med. Sci. 298:278-281; Canonico et al.  
20 (1991) Clin. Res. 39:219A; and Nabel et al. (1990) Science 249:1285-1288. Targeting agents, such as antibodies directed against surface antigens expressed on specific cell types, can be covalently conjugated to the liposomal surface so that the nucleic acid can be delivered to specific tissues and cells for local  
25 administration.

#### Human Gene Therapy and Diagnostic Use of Vector

30 There are several protocols for human gene therapy which have been approved for use by the Recombinant DNA Advisory Committee (RAC) which conform to a general protocol of target cell infection and administration of transfected cells (see for example, Blaese, R.M., et al., 1990; Anderson, W. F., 1992; Culver, K.W. et al., 1991).

In addition, U.S. Patent No. 5,399,346 (Anderson, W. F. et al., March 21, 1995, U.S. Serial No. 220,175) describes procedures for retroviral gene transfer. The contents of these support references are incorporated in their entirety into the subject application.

5 Retroviral-mediated gene transfer requires target cells which are undergoing cell division in order to achieve stable integration hence, cells are collected from a subject often by removing blood or bone marrow. It may be necessary to select for a particular subpopulation of the originally harvested cells for use in the  
10 infection protocol. Then, a retroviral vector containing the gene(s) of interest would be mixed into the culture medium. The vector binds to the surface of the subject's cells, enters the cells and inserts the gene of interest randomly into a chromosome. The gene of interest is now stably integrated and will remain in  
15 place and be passed to all of the daughter cells as the cells grow in number. The cells may be expanded in culture for a total of 9-10 days before reinfusion (Culver et al., 1991). As the length of time the target cells are left in culture increases, the possibility of contamination also increases, therefore a shorter  
20 protocol would be more beneficial.

The basic tasks in the present method of the invention are selecting the proper vector vehicle to deliver the Egr-1 inhibitor to the body and achieving appropriate inhibition of activity of the  
25 Egr-1 protein. The present invention provides packaging the inhibitors in such a way that they can be injected directly or administered directly into the bloodstream or relevant organs of patients who need them. The packaging will protect the inhibitor (e.g., foreign DNA) from elimination by the immune system and  
30 direct it to appropriate tissues or cells.

The methods described below are merely for purposes of illustration and are typical of those that might be used. However, other

procedures may also be employed, as is understood in the art. Most of the techniques used to construct vectors and the like are widely practiced in the art, and most practitioners are familiar with the standard resource materials which describe specific conditions and procedures. However, for convenience, the following paragraphs may serve as a guideline.

#### General Methods for Vector Construction

Construction of suitable vectors containing the desired therapeutic gene coding and control sequences employs standard ligation and restriction techniques, which are well understood in the art (see Maniatis et al., in Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (1982)). Isolated plasmids, DNA sequences, or synthesized oligonucleotides are cleaved, tailored, and religated in the form desired.

Site-specific DNA cleavage is performed by treating with the suitable restriction enzyme (or enzymes) under conditions which are generally understood in the art, and the particulars of which are specified by the manufacturer of these commercially available restriction enzymes (See, e.g. New England Biolabs Product Catalog). In general, about 1  $\mu$ g of plasmid or DNA sequences is cleaved by one unit of enzyme in about 20  $\mu$ l of buffer solution. Typically, an excess of restriction enzyme is used to insure complete digestion of the DNA substrate.

Incubation times of about one hour to two hours at about 37 degree. C. are workable, although variations can be tolerated. After each incubation, protein is removed by extraction with phenol/chloroform, and may be followed by ether extraction, and the nucleic acid recovered from aqueous fractions by precipitation with ethanol. If desired, size separation of the cleaved fragments may



be performed by polyacrylamide gel or agarose gel electrophoresis using standard techniques. A general description of size separations is found in Methods in Enzymology 65:499-560 (1980). Restriction cleaved fragments may be blunt ended by treating with the large fragment of E. coli DNA polymerase I (Klenow) in the presence of the four deoxynucleotide triphosphates (dNTPs) using incubation times of about 15 to 25 min at 20.degree. C. to 25.degree. C. in 50 mM Tris (pH 7.6) 50 mM NaCl, 6 mM MgCl.sub.2, 6 mM DTT and 5-10 .mu.M dNTPs. The Klenow fragment fills in at 5' sticky ends but chews back protruding 3' single strands, even though the four dNTPs are present. If desired, selective repair can be performed by supplying only one of the dNTPs, or with selected dNTPs, within the limitations dictated by the nature of the sticky ends. After treatment with Klenow, the mixture is extracted with phenol/chloroform and ethanol precipitated. Treatment under appropriate conditions with S1 nuclease or Bal-31 results in hydrolysis of any single-stranded portion.

Ligations are performed in 10-50 µl volumes under the following standard conditions and temperatures using T4 DNA ligase. Ligation protocols are standard (D. Goeddel (ed.) Gene Expression Technology: Methods in Enzymology (1991)). In vector construction employing "vector fragments", the vector fragment is commonly treated with bacterial alkaline phosphatase (BAP) or calf intestinal alkaline phosphatase (CIP) in order to remove the 5' phosphate and prevent religation of the vector. Alternatively, religation can be prevented in vectors which have been double digested by additional restriction enzyme digestion of the unwanted fragments.

Suitable vectors include viral vector systems e.g. ADV, RV, and AAV (R. J. Kaufman "Vectors used for expression in mammalian cells" in Gene Expression Technology, edited by D. V. Goeddel (1991)).

Many methods for inserting functional DNA transgenes into cells are known in the art. For example, non-vector methods include nonviral physical transfection of DNA into cells; for example, microinjection (DePamphilis et al., BioTechnique 6:662-680 (1988)); liposomal mediated transfection (Felgner et al., Proc. Natl. Acad. Sci. USA, 84:7413-7417 (1987), Felgner and Holm, Focus 11:21-25 (1989) and Felgner et al., Proc. West. Pharmacol. Soc. 32: 115-121 (1989)) and other methods known in the art.

#### Administration of Modified Vectors Into Subject

One way to get DNA into a target cell is to put it inside a membrane bound sac or vesicle such as a spheroplast or liposome, or by calcium phosphate precipitation (CaPO.sub.4) (Graham F. and Van der Eb, A., Virology 52:456 1973; Schaefer-Ridder M., et al., Liposomes as gene carriers: Efficient transduction of mouse L cells by thymidine kinase gene. Science 1982; 215:166; Stavridis J. C., et al., Construction of transferrin-coated liposomes for in vivo transport of exogenous DNA to bone marrow erythroblasts in rabbits. Exp Cell Res 1986; 164:568-572).

A vesicle can be constructed in such a way that its membrane will fuse with the outer membrane of a target cell. The vector of the invention in vesicles can home into the cancer cells.

The spheroplasts are maintained in high ionic strength buffer until they can be fused through the mammalian target cell using fusogens such as polyethylene glycol.

Liposomes are artificial phospholipid vesicles. Vesicles range in size from 0.2 to 4.0 micrometers and can entrap 10% to 40% of an aqueous buffer containing macromolecules. The liposomes protect the DNA from nucleases and facilitate its introduction into target

cells. Transfection can also occur through electroporation. Before administration, the modified vectors are suspended in complete PBS at a selected density for injection. In addition to PBS, any osmotically balanced solution which is physiologically compatible with the subject may be used to suspend and inject the modified vectors into the host.

For injection, the cell suspension is drawn up into the syringe and administered to anesthetized recipients. Multiple injections may be made using this procedure. The viral suspension procedure thus permits administration of genetically modified vectors to any predetermined site in the skin, is relatively non-traumatic, allows multiple administrations simultaneously in several different sites or the same site using the same viral suspension. Multiple injections may consist of a mixture of therapeutic genes.

#### Survival of the Modified Vectors So Administered

Expression of a gene is controlled at the transcription, translation or post-translation levels. Transcription initiation is an early and critical event in gene expression. This depends on the promoter and enhancer sequences and is influenced by specific cellular factors that interact with these sequences. The transcriptional unit of many prokaryotic genes consists of the promoter and in some cases enhancer or regulator elements (Banerji et al., Cell 27:299 (1981); Corden et al., Science 209:1406 (1980); and Breathnach and Chambon, Ann. Rev. Biochem. 50:349 (1981)). For retroviruses, control elements involved in the replication of the retroviral genome reside in the long terminal repeat (LTR) (Weiss et al., eds., In: The molecular biology of tumor viruses: RNA tumor viruses, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1982)).

Moloney murine leukemia virus (MLV) and Rous sarcoma virus (RSV) LTRs contain promoter and enhancer sequences (Jolly et al., Nucleic Acids Res. 11:1855 (1983); Capecchi et al., In: Enhancer and eukaryotic gene expression, Gulzman and Shenk, eds., pp. 101-102, Cold Spring Harbor Laboratories, Cold Spring Harbor, N.Y.).

Promoter and enhancer regions of a number of non-viral promoters have also been described (Schmidt et al., Nature 314:285 (1985); Rossi and de Crombrughe, Proc. Natl. Acad. Sci. USA 84:5590-5594 (1987)).

In addition to using viral and non-viral promoters to drive therapeutic gene expression, an enhancer sequence may be used to increase the level of therapeutic gene expression. Enhancers can increase the transcriptional activity not only of their native gene but also of some foreign genes (Armelor, Proc. Natl. Acad. Sci. USA 70:2702 (1973)).

The most effective mode of administration and dosage regimen for the molecules of the present invention depends upon the exact location and integrity of the ischemic tissue to be treated, the subject's health and response to treatment and the judgment of the treating physician. Accordingly, the dosages of the compounds (inhibitors) should be titrated to the individual subject. The compounds may be delivered directly or indirectly via another cell, autologous cells are preferred, but heterologous cells are encompassed within the scope of the invention.

The interrelationship of dosages for animals of various sizes and species and humans based on  $\text{mg/m}^2$  of surface area is described by Freireich, E. J., et al. Cancer Chemother., Rep. 50 (4):219-244 (1966). Adjustments in the dosage regimen may be made to optimize the tumor cell growth inhibiting and killing response, e.g., doses

may be divided and administered on a daily basis or the dose reduced proportionally depending upon the situation (e.g., several divided dose may be administered daily or proportionally reduced depending on the specific therapeutic situation).

5

It would be clear that the dose of the molecules of the invention required to achieve cures may be further reduced with schedule optimization.

10

This invention is illustrated in the Experimental Details section which follows. These sections are set forth to aid in an understanding of the invention but are not intended to, and should not be construed to, limit in any way the invention as set forth in the claims which follow thereafter.

03643339-03643339

## EXPERIMENTAL DETAILS

### Example 1: Early Growth Response (Egr-1) Is a Master Switch In the Pathogenesis of Ischemic Stress

Abbreviations used: Egr, early growth response; EMSA, electrophoretic mobility shift assay; ICAM, intercellular adhesion molecule; HIF, hypoxia inducible factor; IL, interleukin; I/R, ischemia/reperfusion; ISH, in situ hybridization; JE/MCP-1, macrophage chemotactic protein-1; L32, ribosomal structural protein; LT $\beta$ , lymphotoxin  $\beta$ ; MIF, macrophage migration inhibitory factor; MIP, macrophage inflammatory protein; MP, mononuclear phagocyte; PAI, plasminogen activator inhibitor; TF, tissue factor; and, VEGF, vascular endothelial growth factor.

Activation of the zinc finger transcription factor Early growth response (Egr)-1<sup>1-2</sup>, initially linked to developmental processes <sup>3</sup>, is shown here to function as a master switch tripped by ischemia to trigger expression of pivotal regulators of coagulation, inflammation and vascular hyperpermeability. Deletion of the Egr-1 gene strikingly diminished expression of these mediators of vascular injury in a murine model of lung ischemia/reperfusion, and enhanced animal survival and organ function. Rapid activation of Egr-1 in response to oxygen deprivation primes the vasculature for dysfunction manifest during reperfusion. These studies define a central role for Egr-I activation in the pathogenesis of tissue damage in ischemia.

It has long been hypothesized that ischemia primes mechanisms leading to reperfusion injury and sets the stage for an exaggerated, maladaptive vascular response eventuating in tissue damage. Hypoxemia, a central component of the ischemic vascular milieu, has been defined as a key factor initiating vascular

injury. To date, the cellular response to oxygen deprivation has largely been defined by studies of the transcription factor HIF (Hypoxia-Inducible Factor)-1<sup>4-6</sup>. Activation of HIF-1 by hypoxia/hypoxemia facilitates metabolic adaptation to environmental challenge; glucose uptake by the noninsulin-dependent glucose transporter (GLUT1) is enhanced, and expression of glycolytic enzymes, erythropoietin and Vascular Endothelial Growth Factor (VEGF) is amplified<sup>4-6</sup>. However, another facet of the cellular response to hypoxia has been revealed by the deposition of fibrin in lung vasculature consequent to induction of procoagulant tissue factor<sup>7</sup>. As tissue factor expression depended on hypoxia-mediated activation of Egr-1 within minutes of oxygen deprivation (and was independent of HIF-1)<sup>7,8</sup>, we tested the hypothesis that induction/activation of Egr-1 might link a broad spectrum of mechanisms underlying vascular dysfunction early in ischemia to events triggering tissue injury during later reperfusion.

## RESULTS

*Egr-1 regulation of coagulation-related cofactors and VEGF.* Because of its rich vascular network, the lung provided an ideal model system to assess the role of Egr-1 in susceptibility to ischemia-induced vascular dysfunction. Egr-1 null mice<sup>9</sup> and age/strain-matched littermate controls were subjected to left lung ischemia<sup>10</sup>. We first sought evidence for Egr-1-mediated regulation of a range of procoagulant and proinflammatory factors. Transcripts for tissue factor (TF), the trigger of the procoagulant pathway *in vivo*, increased ~15-fold in the I/R lung of wild-type mice ( $p < 0.01$ ) compared with Egr-1 null mice in whom only ~3-fold enhancement was seen (Fig. 1A). *In situ* hybridization (ISH) showed virtually undetectable tissue factor mRNA in lungs of control (noninstrumented) wild-type mice (Fig. 1B-1), whereas after I/R, transcripts were evident in lung vasculature (Fig. 1B-2) and

mononuclear phagocytes (MPs) (Fig. 1B-3; B-4 shows colocalization with F4/80 immunoreactivity, a MP marker, in an adjacent section). Consistent with these results, immunostaining showed low levels of tissue factor antigen in uninstrumented lungs from wild-type mice (Fig. 1C-1), whereas I/R caused striking induction of tissue factor antigen in the vasculature (Fig. 1C-2) and MPs. In contrast, the I/R lung from Egr-1 null mice displayed virtually no increase in tissue factor antigen compared with wild-type mice (Fig. 1C-3,4).

An important determinant of fibrin deposition is its clearance by the fibrinolytic system. Plasminogen activator inhibitor (PAI)-1 is the major inhibitor of tissue- and urokinase-type plasminogen activators<sup>11,12</sup>. Lung I/R in wild-type mice induced ~12-fold increase in mRNA for PAI-1 ( $p < 0.01$ ) compared with Egr-1 null animals in whom only ~3-fold increase was observed (Fig. 1D). ISH showed elevated PAI-1 transcripts in lung vasculature (Fig. 1E-2) and MPs (1E-3,4) of wild-type mice after I/R, compared with uninstrumented controls (Fig. 1E-1). By immunostaining, enhanced PAI-1 antigen was closely associated with the vasculature in lungs of wild-type mice subject to I/R (Fig. 1F-2; PAI-1 antigen was also present in MPs), compared with low levels of PAI-1 in lungs from control animals (Fig. 1F-1). Similar studies with Egr-1 null mice showed low levels of PAI-1 antigen in the lung even with I/R (Fig. 1F-4; F-3 shows uninstrumented lung from an Egr-1 null animal). Thus, the two critical determinants of vascular fibrin formation/deposition, expression of tissue factor and PAI-1, are regulated by Egr-1 in I/R.

Egr-1 was next investigated for its potential to regulate expression of another key vascular homeostatic mediator, VEGF. The latter was first identified by its effect on vascular permeability, in addition to its angiogenic properties<sup>13,14</sup>. Rapid induction of VEGF has been observed in models of cerebral ischemia<sup>15</sup> and,



clinically, in myocardial infarction<sup>16</sup>. Furthermore, antagonism of VEGF has been shown to reduce stroke volume, and associated tissue edema, in a murine model<sup>17</sup>, consistent with a pathogenic role for this angiogenic factor in ischemic tissue injury. The lung of wild-type mice subject to I/R demonstrated ~11-fold induction of VEGF mRNA ( $p < 0.01$ ), in contrast to Egr-1 null mice in whom there was only ~2.6-fold increase (Fig. 2A). By ISH, although VEGF transcripts were virtually undetectable in lungs from control wild-type mice (Fig. 2B-1), following I/R, the lung showed a striking increase in VEGF mRNA in the vasculature (Fig. 2B-2) and in MPs (Fig. 2B-3,4). VEGF antigen in wild-type mice was localized to the vasculature of the reperfused lung (Fig. 2C-2), versus undetectable levels in control lung (Fig. 2C-1). In contrast, the I/R lung from Egr-1 null mice displayed undetectable antigen (Fig. 2C-4; C-3 shows lung from a control Egr-1 null mouse). These data demonstrate a previously unrecognized role for Egr-1 in regulation of VEGF subsequent to I/R injury.

*Egr-1 regulation of ICAM-1, and cytokine/chemokines.* A central facet of tissue injury in I/R results from exaggeration of the inflammatory response. An increase of ~17-fold in mRNA for Intercellular Adhesion Molecule (ICAM)-1 was observed in the lung from wild-type mice subject to I/R ( $p < 0.01$ ) versus only ~2.2-fold increase in the I/R lung from Egr-1 null mice (Fig. 3A). The striking induction of ICAM-1 in wild-type mice is consistent with its known role in ischemic tissue damage. ISH demonstrated low levels of ICAM-1 mRNA in uninstrumented lungs from wild type mice (Fig. 3B-1), whereas the I/R lung displayed strong expression of ICAM-1 transcripts in the vasculature (Fig. 3B-2) and MPs (Fig. 3B-3,4). ICAM-1 antigen in wild-type mice was prominent in the vasculature of the reperfused lung (Fig. 3C-2), whereas only low levels of ICAM-1 immunoreactivity were observed in control lung (Fig. 3C-1). In contrast to these results in wild type mice, the

I/R lung of Egr-1 null animals displayed only low levels of ICAM-1 antigen (Fig 3C-4; C-3 shows a control Egr-1 null mouse).

Furthermore, proinflammatory cytokines and chemokines have been  
5 proposed to contribute importantly to tissue injury in I/R, both  
through their direct effects and by induction of cofactors/cell  
adhesion molecules such as tissue factor, PAI-1 and ICAM-1. For  
example, induction of Interleukin (IL)-1 has been noted in the  
immediate reperfusion period in a heterotopic mouse transplant  
10 model, and administration of IL-1 receptor antagonist improved  
graft survival<sup>19</sup>. Enhanced expression of IL-1 also occurs in models  
of tissue ischemia, including those involving renal, hepatic, brain  
and peripheral nerve<sup>20-23</sup>. Interleukin (IL)-1 $\beta$  mRNA was increased  
~21 -fold in the I/R lung of wild-type mice ( $p < 0.01$ ) compared with  
15 Egr-1 null animals in which only ~2.6 fold enhancement was seen  
(Fig. 4A). ISH localized IL-1 $\beta$  transcripts to the vasculature  
(Fig. 4B2) and MPs (Fig. 4B-3,4) of the reperfused lung. This  
distribution of IL-1 $\beta$  mRNA was strikingly similar to that observed  
for tissue factor transcripts (Fig. 1B). IL-1 $\beta$  mRNA levels were  
20 low in lungs from wild-type mice not undergoing the I/R protocol  
(Fig. 4B-1). Consistent with elevated IL-1 $\beta$  transcripts after I/R,  
ELISA of sera from wild-type mice subjected to lung I/R displayed  
~20-fold increase in IL-1 $\beta$  antigen (Fig. 4C;  $p < 0.01$ ). In contrast,  
Egr-1 null mice showed only low levels of IL-1 $\beta$  in response to I/R;  
25 IL-1 $\beta$  antigen was barely above the baseline in mouse sera (Fig.  
4C).

Indeed, this pattern of vascular and MP expression of IL-1 $\beta$ , which  
occurred in an Egr-1-dependent manner, included multiple  
30 chemokines. For example, upregulation of Macrophage inflammatory  
Protein (MIP)-2, a CXC chemokine with prominent effects on  
neutrophils<sup>24,25</sup>, has previously been demonstrated in renal, hepatic  
and hindlimb ischemia models<sup>20,26-21</sup>. Furthermore, MIP-2 has been

shown to have a pathogenic role in ischemic hindlimb injury<sup>29</sup>. Northern analysis showed ~16-fold induction of MIP-2 transcripts in the I/R lung from wild-type mice ( $p < 0.01$ ), whereas Egr-1 null mice showed only ~3-fold increase (Fig. 4D). Such MIP-2 transcripts in the reperfused lung from wild-type mice were localized to the vasculature (Fig. 4E-2), as well as to MPs (Fig. 4E-3,4), by ISH, whereas only low levels of MIP-2 mRNA were observed in uninstrumented mice (Fig. 4E-1). ELISA demonstrated ~15-fold rise in MIP-2 antigen in sera of wild-type mice undergoing lung L/R (Fig. 4F;  $p < 0.01$ ), whereas MIP-2 antigen was barely above the limit of detection in Egr-1 null mice. Induction of Macrophage Chemotactic Protein (JE/MCP)-1, a CC chemokine well-known for its chemotactic and activating effects on monocytes<sup>24,25</sup>, has been shown in a model of cerebral ischemia in rats<sup>30</sup>. Transcripts for JE/MCP-1 were ~17-fold increased in the I/R lung of wild-type mice ( $p < 0.01$ ) versus only a slight increase in Egr-1 null mice (Fig. 4G). ISH again showed the predominant site for JE/MCP-1 transcripts to be the vasculature (Fig. 4H-2) and MPs (Fig. 4H-3,4), whereas little expression was observed in lungs from control mice (Fig. 4H-1). A 15-fold elevation in JE/MCP-1 antigen was detected in sera from wild-type mice subjected to lung I/R ( $p < 0.01$ ), whereas Egr-1 null mice showed only ~2.5-fold increase (Fig. 4I).

These data demonstrate that in I/R, Egr-1 mediates induction of IL-1 $\beta$  and chemokines from both CC and CXC classes. Such mediators amplify pathogenicity by recruiting/activating cellular targets in the blood, such as neutrophils, monocytes and lymphocytes, as well as cells of the vessel wall, including endothelium and smooth muscle cells. The power of this mechanism was further shown by studies demonstrating Egr-1-dependent induction of transcripts for other chemokines, such as IP-10, a CXC chemokine<sup>24,25</sup> previously reported to be expressed in cerebral and hepatic ischemia<sup>26,11</sup>, and RANTES, a CC chemokine<sup>24,25</sup>. In the I/R lung from wild-type mice,

Northern analysis showed ~14-fold increase in IP-10 (Fig. 4J;  $p < 0.01$ ) and ~13-fold increase in RANTES transcripts (Fig. 4K;  $p < 0.01$ ). In contrast, the I/R lung from Egr-1 null animals showed little increase in either IP-10 or RANTES transcripts (Fig. 4J-K).

5 Studies of transcripts for chemokine receptors (CCR1, 2, 3 & 5, CXCR2, CXCR4) demonstrated detectable levels which remained the same or increased in the I/R lung, indicating the likelihood that the chemokines produced under these conditions were capable of exerting their effects on cellular properties. It is important to

10 note that the Egr-1 genotype of the animals did not affect all genes whose expression was induced by I/R. For example, in the I/R lung, transcripts for Lymphotoxin  $\beta$  (LT $\beta$ ) increased comparably with tissue from wild-type and Egr-1 null mice, as demonstrated by ribonuclease protection assays (Fig. 4L; ~10-fold in each case).

15 Furthermore, expression of other proinflammatory genes was not affected by I/R, as demonstrated by the lack of change in levels of transcripts for Macrophage Migration Inhibitory Factor (MIF) in wild-type and Egr-1 null mice with or without I/R (Fig. 4L; note, L32 is a ribosomal structural protein used as a control).

20 *Expression of Egr-1 in lung I/R.* Based on our observations concerning Egr-1 regulation of gene expression in I/R, we anticipated that Egr-1 induction and activation would occur early during the ischemic period. Northern analysis of RNA harvested

25 from wild-type mice displayed increased Egr-1 transcripts in the ischemic lung within 15 min (~3.3-fold;  $p < 0.05$ ; Fig. 5A), which rose further in the ischemic period (~10-13-fold;  $p < 0.01$ ), and were even more elevated by reperfusion (~20-fold;  $p < 0.01$ ). In contrast, mRNA for another transcription factor, Sp1, was not significantly

30 altered in the I/R lung. ISH of the I/R lung from wild-type mice localized Egr-1 mRNA to the vasculature (Fig. 5B-2) and MPs (Fig. 5B-3,4) compared with uninstrumented controls (Fig. 5B-1). Consistent with these data, immunoblotting of nuclear extracts

prepared from lung tissue of wild-type mice with anti-Egr-1 IgG (Fig. 5C) showed an immunoreactive band of increased intensity by 30 min (Fig. 5C, lane 2; 5D shows quantitation), compared with uninstrumented controls (lane 1). This band was further enhanced by 60 min of ischemia (lane 4; =10-fold;  $p < 0.01$ ) and even more by subsequent reperfusion (lane 5; =12-fold;  $p < 0.01$ ). In contrast, there was no change in levels of Sp1 in nuclear extracts from the I/R lung (Fig. 5C, lanes 6-10). Immunostaining showed virtually undetectable Egr-1 in control lungs (Fig. 5E-1), whereas the I/R lung displayed striking expression of Egr-1 antigen in the vasculature (Fig. 5E-2) and MPs. Electrophoretic mobility shift analysis (EMSA) with Egr probe and nuclear extracts prepared from I/R lung of wild-type mice (Fig. 5F; 5H shows quantitation) demonstrated a clearly enhanced gel shift band within 30 min of ischemia (Fig. 5F, lane 4) whose intensity increased over the 60 min ischemic period (lane 5) and was slightly further enhanced by I/R (lane 6), compared with a virtually undetectable signal in control mice (lane 2). That this gel shift band was due to Egr-1 interaction with its cognate DNA binding site was shown in supershift assays with anti-Egr-1 IgG (lane 7-8), but not nonimmune IgG (lane 9-10), and by competition assays in which unlabeled Egr probe blocked (lane 11 - 12), but unlabeled Sp 1 probe did not block appearance of the gel shift band (lane 13-14). In contrast, EMSA with Sp1 probe and nuclear extracts from lung subject to I or I/R did not display a change in intensity of the gel shift band (Fig. 5G, lanes 2-6), and, thus, Sp1 was used to standardize the change in intensity of the Egr-1 gel shift band (Fig. 5H). These data are consistent with the previously observed association of Egr-1 induction and/or activation with renal and cardiac ischemia<sup>32-34</sup>. However, by themselves, such studies cannot establish a causal relationship between Egr-1 and ischemic damage.

*Effect of Egr-1 on the outcome of lung I/R.* The critical test of

these concepts, then, was whether tissue injury in Egr-1 null mice would be diminished in response to lung L/R. Following a 1 hr period, in which blood flow to the left lung was blocked, perfusion was restored for 3 hrs. Then, function of the ischemic/reperfused (I/R) left lung was assessed after preventing blood flow to the light lung (i.e., the animal was dependent on the lung subject to I/R). Compared with wild-type mice, mortality was reduced ( $p=0.037$ ) and arterial oxygen tension was increased ( $p=0.009$ ) in Egr-1 null mice (Fig. 6A-B). Two other parameters closely linked to lung injury, fibrin deposition and leukocyte sequestration, were decreased in Egr-1 null mice (Fig. 6C-D). Compared with control/uninstrumented mice, in whom tissue fibrin content remained low (Fig. 6C, lane 1), time dependent fibrin deposition, detected by immunoblotting of plasmin-digested tissue extracts, was observed in the left lung of wild-type mice by 1 hr of ischemia (Fig. 6C, lane 2). Fibrin deposition in the I/R lung was further amplified during the next 3 hrs of reperfusion (Fig. 6C, lane 3-5). In contrast, fibrin in the I/R lung of Egr-1 null mice was present at much reduced levels (Fig. 6C, lanes 7-10). Leukocyte accumulation, a hallmark of reperfusion injury<sup>35</sup>, was also evident in the I/R lung from wild-type mice, based on measurement of myeloperoxidase activity in tissue extracts. Myeloperoxidase activity in I/R lung was significantly reduced in Egr-1 null mice (Fig. 6D;  $p=0.001$ ). Finally, vascular permeability in the reperfused lung, based on a ratio of wet/dry weight, was also decreased in Egr-1 null mice compared with wild-type controls (Fig. 6E;  $p=0.026$ ). These data suggested that Egr-1 did participate in regulating activation of coagulation, leukocyte accumulation, and vascular permeability in the I/R lung, each of which has an important impact on end-organ function.

*Triggering of Egr-1 activation in ischemia program the cytokine/chemokine response to I/R. Taken together, our findings*

suggested that rapid expression and activation of Egr-1 in the ischemic lung at the earliest stages of oxygen deprivation might serve as the trigger for subsequent induction of mediators regulating vascular and leukocyte/NV properties. To assess this, animals underwent normobaric hypoxia (6% oxygen) without reperfusion and lung RNA was analyzed one hour later to detect IL-1 $\beta$ , MIP-2, and JE/MCP-1 transcripts by ribonuclease protection assays (Fig. 7A). In each case, the level of cytokine/chemokine mRNA was strongly elevated in wild-type mice exposed to hypoxia (~12-, 17- and 10-fold, respectively;  $p < 0.01$ , in each case) compared with minimal to absent expression in mice lacking Egr-1. ISH showed mRNA for IL-1 $\beta$  and these chemokines (MIP-2 and JE/MCP-1) to be localized in the vasculature and MPs, analogous to the distribution of these transcripts in the lung subjected to I/R. In contrast to this suppression of Egr-1-mediated events in the knockout mice, levels of transcripts for LT $\beta$  were comparably increased in wild-type and Egr-1 null mice subjected to hypoxia (~10-fold in each case), and there was no effect of hypoxia on mRNA for MIF, L32 or IL-7 (Fig. 7B).

## DISCUSSION

These data provide insight into a previously unidentified role for Egr-1 as a master switch regulating a range of effector mechanisms underlying ischemic stress. The approximately parallel induction of tissue factor, PAI-1, ICAM-1 and VEGF, as well as IL-1 $\beta$  and chemokines (both ELR, such as IP-10, and ELR+, such as MIP-2)<sup>24-25</sup>, with respect to the timing and sites for their expression, is consistent with rapid Egr-1 induction/activation early in hypoxia, rather than a mechanism in which one mediator, such as IL-1 $\beta$ , is expressed proximally and causes downstream expression of the others. However, following I/R, the lung is bathed in an environment rich in IL-1 $\beta$ , JE/MCP-1 and VEGF, and these factors (as

well as others) could certainly amplify fibrin accumulation, initiated by a more proximal effect of Egr-1 on expression of tissue factor and PAI-1<sup>16-11</sup>. Similarly, the ICAM-1 promoter has been shown to have functional Egr-1 DNA binding motifs<sup>39</sup>, allowing for direct induction of ICAM-1 by Egr-1, which may be augmented by the action of IL-1 $\beta$  and chemokines in the ischemic lung<sup>36</sup>. Although *in vitro* studies have shown VEGF expression to be under control of both HIF-1<sup>40</sup> and Egr-1<sup>41</sup>, the Egr-1 null mouse subject to ischemia did not display enhanced VEGF expression, consistent with the proposed central role for Egr-1 in ischemic stress.

There are several possible mechanisms through which Egr-1 could exert such global effects in IR. First, the Egr-1 DNA binding motif is present in a range of genes relevant to vascular homeostasis and dysfunction<sup>42</sup>, and lack of Egr-1 could directly attenuate expression of the respective mRNAs. Second, absence of Egr-1 might allow its corepressors, especially the inducible molecule Nab-2<sup>43</sup>, to interact with other transcription factors affecting regulation of a spectrum of genes. Additional mechanisms can be envisioned whereby deletion of Egr-1 destabilizes yet to be identified complexes of transcriptional regulators in which its participation facilitates assembly and function. Although further studies will be required to dissect such underlying mechanisms, our results highlight a prominent role for Egr-1 in the pathogenesis of ischemic stress. Indeed, rapid activation and induction of Egr-1 after oxygen deprivation suggest that early in ischemia molecular events programming the vascular response during reperfusion, in fact, are well underway. These data contrast with NF-KB, another transcription factor contributing to control of the host response in ischemia<sup>44,45</sup>, but one which also has important protective properties<sup>46,47</sup>.

Finally, in view of the virtually normal phenotype of Egr-1 null



mice<sup>9</sup> (i.e., no essential homeostatic processes are interrupted), our data suggest that short-term antagonism of Egr-1 may provide an unexpected therapeutic target to diminish maladaptive host responses incited by acute ischemia.

## METHODS

*Murine model of I/R.* Egr-1 null and wild-type mice were subjected to the I/R procedure according to protocols approved by the IACUC at Columbia University, and in accordance with the AALAC guidelines. Both Egr-1 null and wild-type controls (8-12 weeks old) were in a similar mixed background (129xC57BL6). Left lung ischemia was performed as described<sup>10</sup>.

*Survival experiments.* The surgical operator was blinded by a colleague in the laboratory as to mouse genotype. For all groups, the experimental procedures were as follows. After one hour of ischemia, followed by 3 hours of reperfusion, the contralateral (right) hilum was permanently ligated, so that the animal's survival and gas exchange depended solely on the reperfused left lung for 30 min. Survival during this period was defined as described<sup>10</sup>, and is shown in Fig. 6A. Arterial blood gas analysis (sampled from the left ventricle) was performed in mice which survived the 30 min period after right hilar ligation. Wet/dry lung ratio was determined in mice subjected to I/R and sacrificed immediately thereafter. The left hilum was ligated and then the left lung (including residual blood) was harvested and weighed (wet weight). The lung specimen was desiccated at 80°C for 24 hrs and weighed again as dry weight. Wet weight was divided by dry weight to calculate the wet/dry ratio<sup>10</sup>.

*Myeloperoxidase activity in lung* homogenized in hexadecyltrimethylammonium bromide followed by three freeze/thaw

cycles to release the enzyme from leukocyte granules was measured as described<sup>48</sup>.

Immunocytochemical studies were performed on formalin-fixed, paraffin-embedded pieces of lung using the following primary antibodies: goat anti-mouse VEGF IgG (20  $\mu$ g/ml; R&D), sheep anti-mouse PAI-1 IgG (2  $\mu$ g/ml; American Diagnostica), goat anti-mouse IL-1 $\beta$  IgG (2  $\mu$ g/ml; R&D), rabbit anti-Egr-1 IgG (8  $\mu$ g/ml; Santa Cruz), rat F4/80 monoclonal antibody (10  $\mu$ g/ml; PharMingen), rabbit anti-tissue factor IgG (63  $\mu$ g/ml)<sup>7</sup>, and hamster anti-murine ICAM-1 IgG (10  $\mu$ g/ml; PharNfingen). Secondary antibodies (affinity-purified alkaline phosphatase-conjugated antirabbit, anti-sheep, anti-goat and anti-rat IgG's, and biotinylated anti-hamster IgG) and substrates were employed as described previously<sup>8</sup>. In each case, studies were performed with the same species and concentration of nonimmune IgG and specific antibody. Results are shown with the specific antibody, and studies with nonimmune IgG displayed only background levels of staining.

*In situ hybridization.* Murine cDNA's for IL-1 $\beta$ , MIP-2, JE/MCP-1, VEGF, ICAM-1, PAI-1, Egr-1 and tissue factor were prepared by RT-PCR with primers whose sequence was selected based on Genebank. After DNA sequencing, the cDNA's were cloned into PCR-II (InVitrogen) or pGEMT Vector (Promega). Plasmids were then linearized for *in vitro* run-off synthesis to prepare sense and antisense RNA probes, and *in situ* hybridization was performed on lung as described<sup>49</sup>. Sections were counterstained with methylene green (1%; Sigma). In each case, experiments were performed with sense and antisense riboprobes for the indicated marker. Data are displayed with the antisense probe, and studies with the sense probe showed only background staining.

*Northern analysis.* Total RNA was extracted from lung, followed by

electrophoresis, transfer to Duralon-UV membranes (Stratagene) and hybridization with  $^{32}\text{P}$ -labeled cDNA probes for mouse Egr-1<sup>8</sup>, tissue factor<sup>7</sup>, ICAM-1 (ATCC), RANTES (ATCC), IP-10 (ATCC), JE/MCP-1, IL-1 $\beta$ , MIP-2, and VEGF (for the latter three, cDNA's were subcloned as described above). Northern blots were also hybridized with  $^{32}\text{P}$ -labeled  $\beta$ -actin as an internal control for RNA loading. Autoradiograms were analyzed by densitometric scanning from at least three different experiments (a representative autoradiogram is shown in the figures). Absorption values were normalized to the B-actin band, and data shown are mean $\pm$ SEM. Ribonuclease protection assays employed total RNA isolated from the lung and probes for the indicated chemokines/cytokines provided by the manufacturer (Riboquant, PharMingen).

Western blotting of tissue samples for fibrin was performed on lung harvested from animals treated with heparin (10 U/g body weight, resulting in an APTT >300 s) prior to sacrifice<sup>7</sup>. Tissue was subjected to immunoblotting with anti-fibrin antibody as described<sup>7</sup>. Immunoblotting for Egr-1 and Sp1 employed nuclear extracts prepared from lung as described<sup>7</sup>.

ELISAs for IL-1 $\beta$ , MIP-2, and JE/MCP-1 were performed using kits purchased from R&D for murine forms of these mediators. Samples of sera under each experimental condition were obtained from five different mice.

EMSA for Egr-1 utilized nuclear extracts prepared from lungs of mice subjected to the indicated procedure followed by gel shift assay with double-stranded oligonucleotide  $^{32}\text{P}$ -labeled probes for Egr or Sp1 (Santa Cruz) as described<sup>8</sup>. For competition studies, an 100-fold molar excess of unlabeled probes for either Egr (Santa Cruz Biotechnology) or Sp1 (Promega) was added. Supershift assays employed anti-Egr-1 IgG and nonimmune IgG (2  $\mu\text{g}/\text{ml}$  in each case),

also obtained from Santa Cruz.

Induction of hypoxia in mice was performed in animals subjected to normobaric hypoxia (N=5 per experimental condition unless indicated otherwise) for 4 hrs using a previously described chamber with a final oxygen concentration of 5.5-6.5%<sup>7</sup>. Hypoxia resulted in tachypnea and reduced activity, compared with normoxic counterparts, but no mortality occurred.

For statistical analysis, myeloperoxidase activity data were analyzed using the Mann-Whitney U test for unpaired variables, animal survival after lung I/R was evaluated by contingency analysis using the  $\chi^2$  statistic, and serum values of IL-1 $\beta$ , MIP-2 and JE/MCP-1 were analyzed by ANOVA.

**Example 2: Egr-1 suppression in isogeneic rat lung transplant model system**

In an orthotopic, isogeneic rat lung transplant model, Egr-1 expression was studied and the role of suppressing its expression evaluated. Although Egr-1 only increases slightly during hypothermic lung preservation, it increases briskly albeit briefly during reperfusion (Figure 8, Northern blot showing a brisk rise in Egr-1 mRNA following lung reperfusion; Figure 9, a western blot showing a brisk rise in Egr-1 protein following lung reperfusion). To detect the functional significance of this increase in Egr-1 mRNA and protein in the reperfused lungs, an antisense Egr-1 oligodeoxynucleotide was constructed and given into the blood vessels of the donor rat lung using a cationic liposomal carrier, as described in the Methods section. Control (cationic liposomal carrier alone) and a scrambled oligodeoxyribonucleotide (with the same nucleotides, but in random order as the antisense compound), were used to control for non-

sequence specific effects of the carrier or the antisense Egr-1 oligodeoxyribonucleotide. The antisense compound reduced the expression of Egr-1 mRNA by nearly half (Figure 10), and similarly reduced the amount of Egr-1 protein as detected by immunoblotting (Figure 11). When antisense compound was given to the donor rat prior to lung preservation, the function of the graft after transplantation (measured by arterial oxygenation in the recipient which depends entirely upon the transplanted lung) is improved only by the antisense Egr-1 oligodeoxyribonucleotide (Figure 12). Survival of the recipient rat following lung transplantation is improved only by the the antisense Egr-1 oligodeoxyribonucleotide (Figure 13). These data show that Egr-1 expression rises briskly during reperfusion of an ischemic tissue, and that suppressing its expression can have functionally beneficial and improve survival of the entire organism following an ischemic challenge. Because an isogeneic (identical strain) transplant model was used, these results are broadly applicable to ischemia in general, and not restricted just to the transplant setting.

#### Materials and Preparation of Antisense Egr-1 and Lung Transplant Model (Used in Figures 8-13):

##### Materials:

Preservation solution: For all transplant experiments, the basic preservation solution consisted of modified Euro-Collins solution obtained from Baxter Healthcare (Deerfield, IL;  $\text{Na}^+$  10 mEq/L,  $\text{K}^+$  11 mEq/L,  $\text{Cl}^-$  15 mEq/L,  $\text{HPO}_4^{2-}$  85 mEq/L,  $\text{H}_2\text{PO}_4^-$  15 mEq/L,  $\text{HCO}_3^-$  10 mEq/L), modified by adding 10 mL of 10% magnesium sulfate and 50 mL of 50% glucose solution per liter. This represents the standard formulation used in clinical lung transplantation.

Sense and antisense oligonucleotides: Sense and antisense

phosphorothioate oligonucleotides were chemically synthesized and HPLC-purified (GIBCO BRL, Grand Island, NY). Egr-1 antisense oligonucleotide was 5'-CTTGGCCGCTGCCAT-3' (SEQ ID NO:1). The complementary sense sequence used was 5'-TACCGTCGCCGTGCT-3' (SEQ ID NO:2). Cationic liposomal carrier: To transfect the oligonucleotides into cells or pulmonary grafts, a cationic liposomal carrier was used which has demonstrated efficacy and lack of toxicity<sup>7</sup> in pulmonary endothelial cells. The liposome formulation chosen for these experiments was the cationic lipid N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), and dioleoyl phosphatidylethanolamine (DOPE) (GIBCO BRL) to enhance the oligonucleotide uptake by cells.

Other Materials: Unless otherwise specified, chemicals were purchased from either Sigma Chemical Co. (St. Louis, MO) or Boehringer Mannheim Co. (Indianapolis, IN)

Lung transplant experiments: Donor Lung Harvest: Inbred male Lewis rats (250-300 gms) were used for experiments. Donor rats were given 500 units of heparin intravenously, and following ligation of the right pulmonary artery (PA) (to restrict delivery of preservation solution to the donor lung used for grafting), 7 mL of 4°C preservation solution was administered into the main PA at a constant infusion pressure of 20 mm Hg. The left lung was then harvested, a cuff was placed on each vascular stump and the left bronchus, and the lung was submerged for 4 hours in preservation solution maintained at 4°C. Transplantation was performed using gender/strain/size matched recipient rats which were anesthetized, intubated, and ventilated with 100% O<sub>2</sub> using a rodent ventilator. Orthotopic left lung transplantation was performed as described through a left thoracotomy using a rapid cuff technique for all anastomoses, with warm ischemic times maintained below 5 minutes. The hilar cross-clamp was released, re-establishing blood flow and

ventilation to the transplanted lung.

For all experiments, the preservation duration was 4 hours. For those experiments in which oligonucleotides were studied, the base preservation solution was supplemented with lipofectin (350 [Lg/0.8 mL of EuroCollins), which was allowed to equilibrate for 45 minutes at room temperature, followed by the addition of either the sense or the antisense oligonucleotide construct (350  $\mu$ g in an additional 0.8 mL of EuroCollins); this 1.6 mL mixture was allowed to incubate at room temperature for 30 minutes, after which 5.4 mL of EuroCollins solution was added, and the entire mixture chilled to 4°C. This was prepared fresh for each experiment.

After lung transplantation, the right (nontransplanted lung was excluded from the circulation with a ligature, and the function of the left (transplanted) lung was measured. Gas exchange was determined by measuring arterial oxygen tension ( $PO_2$ , mm Hg) using a model ABL-30 gas analyzer from a sample of left atrial blood taken at the final time point at which the recipient was alive (up to 30 minutes). Thirty minutes following ligation of the native right PA, survival was assessed, and transplanted lung was cross-clamped to divide it into equal parts, with one portion being excised, rinsed briskly in physiologic saline, and snap frozen in liquid nitrogen until the time of assays for Egr-1 protein or mRNA expression.

Immunoblotting for Egr-I Protein: For the lung transplant experiments, integral membrane proteins were extracted. Lung tissue was homogenized in TBS buffer containing protease inhibitors, and protein concentrations were determined according to the Bradford method. Samples were prepared for nonreduced SDS-PAGE, with equal amounts of protein (20  $\mu$ g) loaded onto on 7.5% Tris-Glycine gel, subjected to electrophoresis, and

electrophoretically transferred onto a nitrocellulose membrane. After overnight blocking with nonfat dry milk, the membrane was incubated for 3 hours at room temperature with a 1: 1 000 dilution (in nonfat dry milk) of anti-Egr-1 IgG, washed thrice, followed by  
5 a 1 hour room temperature incubation with a 1: 1000 dilution of a horseradish peroxidase-conjugated secondary IgG. Sites of primary antibody binding were visualized by the enhanced chemiluminescence method (for the cell culture experiments) in which blots were developed with Diaminobenzidine in Tris buffer (50 mM). Blots were  
10 scanned into a Macintosh computer for subsequent densitometric analysis.

Northern blotting for Egr-1 mRNA: For analysis of Egr-1 mRNA, total cellular RNA was extracted using an RNA isolation kit. To detect  
15 Egr-1 mRNA, equal amounts of RNA (20  $\mu$ g) were loaded onto a 0.8% agarose gel containing 2.2 M formaldehyde for size fractionation, and then transferred overnight by capillary pressure to nylon membranes with 20X SSC buffer (GIBCO BRL). An Egr-1 cDNA probe was labelled with  $\alpha$ -<sup>32</sup>P-dCTP by random primer labelling, hybridized to  
20 blots at 68°C for 1 hour in hybridization solution, washed twice with 2X SSC/0. 1 % SDS for 15 minutes at room temperature, and once with 0. 1X SSC/0. 1 % SDS for 30 minutes at 60°C. Blots were developed with X-Omat AR film exposed with an intensifying light screen at -70° for 3 to 7 days. Membranes were subsequently  
25 stripped to reprobe for  $\beta$ -actin by boiling in 0. 1X SSC/0. 1 % SDS; the membrane was then hybridized with a  $\beta$ -actin cDNA probe (and developed as described above). Blots were scanned into a Macintosh computer, and Molecular Analysis software used to calculate the density of each band.

30 Sequences: The following are several Egr-1 nucleic acid and protein sequences which are available in GenBank.



LOCUS HSA243425 6590 bp

DNA PRI 03-JUL-2000

DEFINITION Homo sapiens EGR1 gene for early growth response protein 1.

ACCESSION AJ243425 VERSION AJ243425.1 GI:5420378

5 KEYWORDS early growth response protein 1; EGR1 gene.

SOURCE human.

ORGANISM Homo sapiens Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 6590)

10 AUTHORS Slade, J.P. and Carter, D.A.

TITLE Cyclical expression of egr-1/NGFI-A in the rat anterior pituitary: A molecular signal for ovulation?

JOURNAL J. Neuroendocrinol. 12 (7), 671-676 (2000)

MEDLINE 20307414

15 REFERENCE 2 (bases 1 to 6590)

AUTHORS Slade, J.P.

TITLE Direct Submission

JOURNAL Submitted (25-JUN-1999) Slade J.P., School of Biosciences, Cardiff University, PO BOX 911, Museum Avenue, Cardiff, CF1 3US, UNITED KINGDOM

20 FEATURES Location/Qualifiers source 1..6590 /organism="Homo sapiens" /db\_xref="taxon:9606" /clone="ATCC 65848" mRNA join(2370..2957,3644..6198) /gene="EGR1" /product="early growth response protein 1" exon 2370..2957 /gene="EGR1" /number=1 gene 2370..6198 /gene="EGR1" 5'UTR 2370..2650 /gene="EGR1" CDS join(2651..2957,3644..4968) /gene="EGR1" /codon\_start=1 /product="early growth response protein 1" /protein\_id="CAB46678.1" /db\_xref="GI:5420379"

25 /translation=

30 M A A A K A E M Q L M S P L Q I S D P F G S F P H S P T M D N Y P K L E E M M L L S N G  
APQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTA  
ESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSG  
LVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFTPTNTDIFP  
EPQSQAFFGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPPQQGDLGLGTPDQKPFQG  
LESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSqliKPSRMRYPNRPSKTPPH  
ERP YACPVESCDRRFSRSDDELTRHIRIHTGQKPFQCRICMRNFSRSDHLTTTHRTHTG

EKPFACDICGRKFARSDERKRHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSY  
PSPVTTSYPSPATTSYPSVPVTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPA  
QVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC

(SEQ ID NO:3)

5 intron 2958..3643 /gene="EGR1" /number=1 exon 3644..6198 /gene="EGR1" /number=2 3'UTR  
4969..6177 /gene="EGR1" polyA\_signal 6178..6183 /gene="EGR1"

BASE COUNT 1351 a 2048 c 1784 g 1407 t

10  
ORIGIN

1 gcgggctggg gctgtggctc acacctggaa tcccagcact ttgggaggcc gaagtgggtg  
61 aatcgcttga gctcaagagt tcaagaccag cctgggcaac acagcgaaac ccctctctac  
121 gaaaatacaa aaaaaaaaaa aaaaaagtaa aagccaggcg tgggtggcagg cacctgtagt  
15 181 ccaagctact cgagaggagg aggctggagg atcacttgag cctgggaggc ggaggttgca  
241 gtgagctcgc gccactgcac tccaacctgg gtgccagcgt gagaccccg ctcagaaaga  
301 ataaaaacat taaaaaaaaa atttggttaa ggtaccctac caggagtggt caaatggac  
361 attcagacac aaggccatct gcgtgcaac agcctggcct tctgccctt gcggcaggag  
421 tctctgaga ggcgcacac tctgccccca atggacaact ccgtagacag tgggagttag  
20 481 cccccacct cccagcggga cttgagacgg caggctccga gacgaggag tcttggttca  
541 ttaagtgggt ttattataaa aaacatgttt ggagggggga cagccacaaa gggattaagt  
601 ccaagaaagt taccctctcc cccacctaat cccctgacc ccgacctca gaggtgttg  
661 gggtttacag aggcctcac ctctccctt ccctctcgtt gtcgtcaaac accctcttc  
721 tccacatttc tcttctgct ttcttttaa atccagaaaa aacagtacct cctctggatt  
25 781 cagagctaga gcaggaggag ccttccttcc cggaatccct gttcccttg ggggagcaac  
841 tgacggttcg tgggggcggg gaggggtccc cttttgttt gacccaagga agactgggga  
901 atatttctct tagacaccac ccacctttt ttcttttcc cttcacttt gccaggctgg  
961 ggttgaggat tgttatcccg gagtttggc gttcgggaag tgacggttc ccggggttg  
1021 aaggggagcc cgggttaagc gcctgttcag ttcgtgtca tgcgtcgaag gtcccccgg  
30 1081 ccttgctccg cgcccagcg cgcatccggg aggaggagcg aggaggcggc ggaagagccc  
1141 gcgcggcccg agtcggggc tgggagtga gagggaacct ccagggggca gcaccgagcc  
1201 gcaaagccg tctctcttc gcgccagcc cggggtcccc agatagccca tagggaagcc  
1261 cctcttcgg attccgcag tgtgggccg ccctccacct ggactggata aaggggggaa

005280" 58E 94350

1321 agtgaccct caccacaagg accattatct cctggtgaga acaagaatca ggcctctctt  
1381 ggggcaatca gttcccccac ttcggtcccc caaaggtggg ctctttgccg gcgggggacta  
1441 ggggaacagcc ttctggttcc gggggagcac aggggacccc aggcaccagc agcccatcc  
1501 caccgacagg tggcagaggc aaggcagctc actgctatac agtgctccaa gaaccaagtg  
5 1561 gccgtgactt cctatctca atttccagc gacaccgga aagacaccgt gccatagatc  
1621 gaggcccggg gtcaaggccc cgctctctct gggcgcccc tggccaggcg ggccagccg  
1681 ctctccccc gactcccg tctctctca cgtccctga ggtggcggg cgggcctgga  
1741 tgacagcat agaaccgccc ccgactgc cctcgcccc gctctgggtc tgggcttccc  
1801 cagcctagtt cagcctagg agccgctga gcagccgcg ccagcgccac acgccacgag  
10 1861 cctccccgc ctggcgctcc ccggtcccc cgagcgctcg ggctccggc ttggaaccag  
1921 ggaggaggga gggagcgagg gagcaaccag ctcgaccgg aatgcatata gagcaggaag  
1981 gatccccgc cggaacaacc ctatttggg cagcaccta ttggagtgg ccgatatgg  
2041 cccggcgctt ccggtcttg gaggaggga gaaggcgag ggaggggcaa cgcgggaact  
2101 ccggagctgc cgtccccga gggccggcg gcggctagag ctctaggctt cccgaagct  
15 2161 gggcgcttg gatcgggcc gggccgggc ctagggtgca ggatggagt gccggcgct  
2221 gtcgatggg gggttcacg tctccggg tctccccg gtctgcat attagggtt  
2281 ctgcttcca tatatgcat gtacgtcag acggaggcg accgtgccc ttccagacc  
2341 ttcaataga ggcggtccg gggagtcg agatccag ccgcagaact tgggagccg  
2401 ccgcgcat ccgcgcgc agccagctt cgcgcgca ggaccggccc ctgcccagc  
20 2461 ctccgagcc gggcgctc cagccgcc cgcgccagg gcgagtcggg gtcgccct  
2521 gcagcttct cagtgtccc cgcgccgc atgtaaccg gccaggcccc cgcaacggtg  
2581 tccctgcag ctccagcccc gggtgcacc cccccccc gacaccagct ctccagctg  
2641 ctctccagg atggccgcg ccaaggccga gatgcagct atgtccccg tgcagatct  
2701 tgaccgtt gccatcttc ctactgcc caccatggac aactacccta agctggagga  
25 2761 gatgatgtg ctgagcaac gggctccca gttctcggc gccgccccg cccagaggg  
2821 cagcggcagc aacagcagc gcagcagc cgggggcgtt ggaggcgcg gggcgggcag  
2881 caacagcagc agcagcagc gcacttcaa cctcaggcg gacacggcg agcagcccta  
2941 cgagcacctg accgcagga agcagtggc tacgcccagg gggaaccct tcgcccat  
3001 cctggcgctc tctcttcc cgcaggagt ctctggatc ttagaatgag agccgggtt  
30 3061 ccttttatt cctgcctcc ccagatcat gtgttagagg gatgccaagg aacccacac  
3121 agccacccc ctgcccct cctagcgg ggcagagga ccgagcttt gtttggatg  
3181 gagagctct gagctgcgt ggtgggtgga gggggaggc ttgtttgat gagcggggt  
3241 gcgccccac ctccagtaag actgcctg cttgcttc cgctgtccc caaggaagga

5

10

15

20

25

30

5281 atgcctgacc ccttgctccc ttcaatgcta gaaaatcgag ttggcaaat ggggtttggg  
5341 cccctcagag ccctgccctg cacccttgta cagtgtctgt gccatggatt tcgttttct  
5401 tggggctactc ttgatgtgaa gataattgc atattctatt gtattattg gagttaggc  
5461 ctacttggg ggaaaaaaaa aaaaaaaagc caagcaaacc aatggtgac ctctatttg  
5 5521 tgatgatgct gtgacaataa gtttgaacct ttttttga aacagcagtc ccagtattct  
5581 cagagcatgt gtcagagtgt tgttcgta accttttgt aaatactgct tgaccgtact  
5641 ctacatgtg gcaaaatatg gtttggttt tctttttt tttgaaagt gtttttctt  
5701 cgtcctttg gtttaaaaag ttacacgtct tggcgcttt tgtgtgatgc cccttgctga  
5761 tgcttgaca tgtgcaattg tgagggacat gtcacctct agccttaagg ggggcaggga  
10 5821 gtgatgattt gggggaggct ttgggagcaa aataaggaag agggctgagc tgagctcgg  
5881 ttctccagaa tgtaagaaaa caaatctaa acaaaatct gaactctca aagtctattt  
5941 ttttaactga aaatgtaaat ttataaatat attcaggagt tggaatgtg tagttacct  
6001 ctgagtaggc ggcgatttt gtatgttatg aacatgcagt tcattattt gtggttctat  
6061 tttactttgt actgtgttt gctaaacaa agtgactgtt tggctataa acacattgaa  
15 6121 tgcgctttat tgcccatggg atatgtgtg tatatcctc caaaaaatta aaacgaaat  
6181 aaagtagctg cgattgggta tgtgtttcct gggtagggg aaggactctg ccctattgag  
6241 ggctgtgagg tttctgaag acttgccct tagagataca aggatcctcc agccagagtc  
6301 aggccactg tgtgaaactg gagttcgta tttatgagga ctgagtatgg gtcttcaaat  
6361 agggctcgg tctatccacc caggctggag tgcagtagtg taatcacagt tctgcagc  
20 6421 tttggtgtct caggctcaag tgatcctccc acctcagcct cctgagtagc tgggactata  
6481 ggacgtgcc accacactcg gtaatgttt atagagacag ggttttgcca tgttgcccag  
6541 gctggagtc ttctgataa tgggcctgtt cctctcagt ctgttggtg //  
(SEQ ID NO:4)

25 LOCUS NM\_001964 3132 bp mRNA PRI 07-APR-2000

DEFINITION Homo sapiens early growth response 1 (EGR1), mRNA.

ACCESSION NM\_001964

VERSION NM\_001964.1 GI:4503492

KEYWORDS .

30 SOURCE human.

ORGANISM Homo sapiens Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 3132)

AUTHORS Suggs,S.V., Katzowitz,J.L., Tsai-Morris,C. and Sukhatme,V.P.

TITLE cDNA sequence of the human cellular early growth response gene Egr-1

JOURNAL Nucleic Acids Res. 18 (14), 4283 (1990)

MEDLINE 90332455

REFERENCE 2 (bases 1 to 3132)

AUTHORS Mahlknecht U, Bucala R, Hoelzer D and Verdin E.

TITLE High resolution physical mapping of human HDAC3, a potential tumor suppressor gene in the 5q31 region

JOURNAL Cytogenet. Cell Genet. 86 (3-4), 237-239 (1999)

MEDLINE 20044614

PUBMED 10575214

COMMENT REFSEQ: The reference sequence was derived from X52541.1. PROVISIONAL RefSeq: This is a provisional reference sequence record that has not yet been subject to human review. The final curated reference sequence record may be somewhat different from this one.

FEATURES Location/Qualifiers source 1..3132 /organism="Homo sapiens" /db\_xref="taxon:9606" /chromosome="5" /map="5q31.1" /clone="hEGR1.364" /cell\_type="fibroblast 303" /tissue\_type="foreskin" /clone\_lib="lambda-ZAP" gene 1..3132 /gene="EGR1" /note="KROX-24; NGFI-A; TIS8; ZIF-268" /db\_xref="LocusID:958" /db\_xref="MIM:128990" CDS 271..1902 /gene="EGR1" /codon\_start=1 /product="early growth response 1" /protein\_id="NP\_001955.1" /db\_xref="GI:4503493"

/translation="

M A A K A E M Q L M S P L Q I S D P F G S F P H S P T M D N Y P K L E E M M L L S N G  
A P Q F L G A A G A P E G S G S N S S S S S G G G G G G G S N S S S S S T F N P Q A D T G E Q P Y E H L T A  
E S F P D I S L N N E K V L V E T S Y P S Q T T R L P P I T Y T G R F S L E P A P N S G N T L W P E P L F S L V S G  
L V S M T N P P A S S S S A P S P A A S S A S A S Q S P P L S C A V P S N D S S P I Y S A A P T F P T P N T D I F P  
E P Q S Q A F P G S A G T A L Q Y P P P A Y P A A K G G F Q V P M I P D Y L F P Q Q Q G D L G L G T P D Q K P F Q G  
L E S R T Q Q P S L T P L S T I K A F A T Q S G S Q D L K A L N T S Y Q S Q L I K P S R M R K Y P N R P S K T P P H  
E R P Y A C P V E S C D R R F S R S D E L T R H I R I H T G Q K P F Q C R I C M R N F S R S D H L T T H I R T H T G  
E K P F A C D I C G R K F A R S D E R K R H T K I H L R Q K D K K A D K S V V A S S A T S S L S S Y P S P V A T S Y  
P S P V T T S Y P S P A T T S Y P S P V P T S F S S P G S S T Y P S P V H S G F P S P S V A T T Y S S V P P A F P A  
Q V S S F P S S A V T N S F S A S T G L S D M T A T F S P R T I E I C" (SEQ ID NO:5)

BASE COUNT 687 a 1004 c 730 g 711 t

1 ccgcagaact tggggagccg ccgcgcgcac ccgcgcgcgc agccagcttc cgcgcgcga  
61 ggaccggccc ctgccccagc ctccgcagcc ggggcgcgtc cagcccccgc cgcgcccagg  
121 gcgagtcggg gtcgccgct gcacgttct cagtgttccc cgcgccccgc atgtaacccg  
181 gccaggcccc cgcaacggtg tccctgcag ctccagcccc gggctgcacc ccccccccc  
241 gacaccagct ctccagcctg ctgctccagg atggccgcgg ccaaggccga gatgcagctg  
301 atgtccccgc tgcagatctc tgaccgctt ggatccttc ctactcgcc caccatggac  
361 aactacccta agctggagga gatgatgctg ctgagcaacg gggctcccca gtctctcgcc  
421 gccgccgggg cccagagggg cagcggcagc aacagcagca gcagcagcag cgggggcggg  
481 ggaggcggcg ggggcggcag caacagcagc agcagcagca gcacctcaa cctcaggcg  
541 gacacgggcg agcagcccta cgagcacctg accgcagagt ctttctga catctctg  
601 aacaacgaga aggtgtggt ggagaccagt taccagccc aaaccactcg actgcccc  
661 atcacctata ctggccgctt tccctggag cctgcacca acagtggcaa cacttgttg  
721 cccagcccc tctcagctt ggtcagtggc ctagtgagca tgaccaacc accggcctcc  
781 tctctcag caccatctcc agcgccctcc tccgctccg cctccagag cccaccctg  
841 agctgcgcag tgccatcaa cgacagcagt cccatttact cagcggcacc cacttcccc  
901 acgccgaaca ctgacattt cctgagcca caaagccagg ccttcccggg ctgcgcaggg  
961 acagcgtcc agtacccgcc tctgcctac cctgcgcga aggttggtt ccaggttccc  
1021 atgatccccg actacctgtt tccacagcag cagggggatc tgggcctggg cccccagac  
1081 cagaagccct tccagggcct ggagagccgc acccagcagc ctctgctaac cctctgtct  
1141 actattaagg ccttggccac tcagtggggc tccaggacc tgaaggccct caataccagc  
1201 taccagtccc agctcatcaa acccagccgc atgcgcaagt atcccaaccg gccagcaag  
1261 acgccccccc acgaacgccc ttacgcttgc ccagtggagt cctgtgatc cgccttctcc  
1321 cgtccgacg agctcaccg ccacatccgc atccacacag gccagaagcc ctccagctgc  
1381 cgcactgca tgcgaactt cagccgcagc gaccacctca cccccacat cgcaccac  
1441 acaggcgaag agcccttgc ctgcgacat tgtggaagaa agtttgccag gagcgatgaa  
1501 cgcaagaggc ataccaagat ccacttgcgg cagaaggaca agaaagcaga caaaagtgtt  
1561 gtggcctctt cggccacctc ctctctctct tctacctgt ccccggttgc tactcttacc  
1621 ccgtccccgg ttactacctc ttatccatcc ccggccacca cctcataccc atcccctgtg  
1681 cccacctct tctctctcc cggctctcg acctacccat cccctgtgca cagtggcttc  
1741 cctccccctt cgttgccac cagctactcc tctgttccc ctgcttccc gcccaggtc

5

10

15

20



## References

1. Mirandt, J. A nerve growth factor induced gene encodes a possible transcriptional regulatory factor. Science 238, 797-799 (1988).
2. Gashler, A. & Sukhatme, V. Egr-1: prototype of a zinc finger fan-lily of transcription factors. Prog. Nucl. Acids Res. and Molec. Biol. 50, 191-224 (1995).
3. Nguyen, H., Hoffman-Lieberman, B. & Liebenmann, D. Egr-1 is essential for and restricts differentiation along the macrophage cell lineage. Cell 72, 197-209 (1993).
4. Semenza, G. Perspectives on oxygen sensing. Cell 98, 281-284 (1999).
5. Zhu, H. & Bunn, H. Oxygen sensing and signaling: impact on the regulation of physiologically important genes. Respir Physiol 115, 239-247 (1999).
6. Ratcliffe, P., O'Rourke, J., Maxwell, P. & Pugh, C. Oxygen sensing, HIF-1 and the regulation of mammalian gene expression. J. Exp. Biol. 201, 1153-1162 (1998).
7. Yan, S-F., et al. Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proc Natl Acad Sci 95, 8298-8303 (1998).
8. Yan, S-F., et al. Hypoxia-associated induction of Early Growth Response-1 gene expression. J Biol Chem 274, 15030-15040 (1999).
9. Lee, S., et al. Luteinizing hormone deficiency and female

infertility in mice lacking the transcription factor NGFI-A (Egr-1). Science 273, 1219-1221 (1996).

10. Okada, K., et al. Potentiation of endogenous fibrinolysis and rescue from lung ischemia-reperfusion injury in IL-10-reconstituted IL-10 null mice. J. Biol. Chem. epub ahead of print (2000).

11. Collen, D. & Lijnen, H. Fibrin-specific fibrinolysis. Ann N Y Acad Sci 667, 259-271 (1992).

12. Loskutoff, D., Sawdey, M., Keeton, M. & Schneiderman, J. Regulation of PAI-1 gene expression in vivo. Thromb & Haemost 70, 135-137 (1993).

13. Leung, D., et al. VEGF is a secreted angiogenic mitogen. Science 246, 1306-1309 (1989).

14. Dvorak, H., Brown, L., Detmar, M. & Dvorak, A. VPF/VEGF, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146, 1029-1039 (1995).

15. Hayashi, T., Abe, K., Suzuki, H. & Itoyama, Y. Rapid induction of VEGF gene expression after transient middle cerebral artery occlusion in rats. Stroke 28, 2039-2044 (1997).

16. Lee, S., et al. Early expression of angiogenesis factors in acute myocardial ischemia. New Engl J Med 342, 626-633 (2000).

17. VanBruggen, N., et al. VEGF antagonism reduces edema formation and tissue damage in ischemia/reperfusion injury in the mouse brain. J Clin Invest 104, 1613-1620 (1999).

18. Lefer, A. Role of the  $\beta$ 2-integrins and immunoglobulin

superfamily members in myocardial ischemia-reperfusion. *Ann Thorac Surg* 68, 1920-1930 (1999).

19. Wang. C., et al. Cardiac graft ICAM-1 and IL-1 expression  
mediate primary isograft failure and induction of ICAM-1 in organs  
remote from the site of transplantation. *Circ Res* 82, 762-772  
(1998).

20. Lemay, S., Rabb, H., Postler, G. & Singh, A. Prominent and  
sustained upregulation of gpl30-signaling cytokines and the  
chemokine MIP-2 in murine renal ischemia-reperfusion injury.  
*Transplant* 69, 959-963 (2000).

21. Liu, P., et al. Role of endogenous nitric oxide in TNF- $\alpha$  and  
IL-1 $\beta$  generation in hepatic ischemia-reperfusion. *Shock* 13, 217-  
223 (2000).

22. Touzani, O., Boutin, H., Chuquet, J. & Rothwell, N. Potential  
mechanisms of IL-1 involvement in cerebral ischemia. *J*  
*Neuroimmunol* 100, 203-215 (1999).

23. Mitsui, Y. The expression of proinflammatory cytokine mRNA in  
the sciatic-tibial nerve of ischemia-reperfusion injury. *Brain Res*  
844, 192-195 (1999).

24. Rollins, B. Chemokines. *Blood* 90, 909-928 (1997).

25. Kunkel, S. Through the looking glass: the diverse in vivo  
activities of chemokines. *J Clin Invest* 104, 1333-1334 (1999).

26. Colletti, L., Green, M., Burdick, M., Strieter, R. The ratio  
of ELR+ to ELR- CXC chemokines affects the lung and liver injury  
following hepatic ischemia/reperfusion in the rat. *Hepatology* 31,

435-445 (2000).

27. Yoshidome, H., Kato, A., Edwards, M. & Lentsch, A. IL-10 inhibits pulmonary NF-KB activation and lung injury by hepatic ischemia-reperfusion. Am J Physiol 277, L919-L923 (1999).

28. Lentsch, A., et al. Chemokine involvement in hepatic ischemia/reperfusion injury in mice: roles for MIP-2 and KC. Hepatology 27, 1172-1177 (1998).

29. Bless, N., et al. Roles for C-X-C chemokines and C5a in lung injury after hindlimb ischemia-reperfusion. Am J Physiol 276, L57-L63 (1999).

30. Gourmala, N., et al. Differential and time-dependent expression of JE/MCP-1 mRNA by astrocytes and macrophages in rat brain: effects of ischemia and peripheral LPS administration. J Neuroimmunol 74, 35-44 (1997).

31. Wang, X., et al. Prolonged expression of IP-10 in ischemic cortex after permanent occlusion of the middle cerebral artery in rat. J Neurochem 71, 1194-1204 (1998).

32. Brand, T., et al. Proto-oncogene expression in porcine myocardium subjected to ischemia and reperfusion. Circ Res 71, 1351-1360 (1992).

33. Ouellette, A., Malt, R., Sukhatme, V., Bonventre, J. Expression of two "immediate early" genes, Egr-1 and c-fos, in response to renal ischemia and during compensatory renal hypertrophy in mice. J Clin Invest 85, 766-771 (1990).

34. Safirstein, R., Price, P., Saggi, S., Har-fis, R. Changes in

gene expression after temporary renal ischemia. *Kidney Intl* 37, 1515-1521 (1990).

35. Weiss, S. Tissue destruction by neutrophils. *New Engl J Med* 320, 365-376 (1989).

36. Pober, J., & Cotran, R. Cytokines and endothelial cell biology. *Physiol. Revs.* 70,427-451 1990).

37. Schechter, A., et al. Tissue factor is induced by MCP-1 in human aortic smooth muscle and THP-1 cells. *J Biol Chem* 272, 28568-28573 (1997).

38. Clauss, M., et al. VEGF: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. *J Exp Med* 172, 1535-1545 (1990).

39. Maltzman, J., Carmen, J., Monroe, J. Transcriptional regulation of the ICAM-1 gene in antigen receptor- and phorbol ester-stimulated B lymphocytes: role for transcription factor Egr-1. *J Exp Med* 183,1747-1759 (1996).

40. Forsythe, J., et al. Activation of VEGF gene transcription by HIF-1. *Molec Cell Biol* 16, 4604-4613 (1996).

41. Mechtcheriakova, D., et al. VEGF-induced tissue factor expression in endothelial cells is mediated by Egr-1. *Blood* 93, 3 811-3123 (1999).

42. Khachigian, L., Lindner, V., Williams, A. & Collins, T. Egr-1-induced endothelial gene expression: a common theme in vascular injury. *Science* 271, 1427-1431 (1996).

43. Svaren, J., et al. NAB2, a corepressor of NGFI-A (EGR-1), and Krox20, is induced by proliferative, and differentiative stimuli. *Mol Cell Biol* 16, 3545-3553 (1996).
- 5 44. Morishita, R., et al. In vivo transfection of cis element "decoy" against NF-KB binding site prevents myocardial infarction. *Nat. Med.* 3, 894-899 (1997).
- 10 45. Schneider, A., et al. NF-KB is activated and promotes cell death in focal cerebral ischemia. *Nat. Med.* 5, 554-550 (1999).
- 15 46. Millet, I., et al. Inhibition of NF-KB activity and enhancement of apoptosis by neuropeptide CGRP. *J. Biol. Chem.* 275,15114-15121 (2000).
- 20 47. Cahir-McFarland, E. NF-KB inhibition causes spontaneous apoptosis in EB virus-transformed lymphoblastoid cells. *Proc. Natl. Acad. Sci.* 97, 6055-6060 (2000).
- 25 48. Goldblum, S., Wu, K. & Jay, M. Lung myeloperoxidase as a measure of pulmonary leukostasis in rabbits. *J App Physiol* 59, 1978-1985 (1985).
49. Ikomminoth, P. Detection of mRNA in tissue sections using DIG-labeled RNA and oligonucleotide probes. In, *Nonradioactive In Situ Hybridization Application Manual*, 2nd Edition, Boehringer-Mannheim, pp. 126-135 (1996).

What is claimed is:

1. A method for reducing damage to an ischemic tissue which  
5 comprises contacting cells of the tissue with an inhibitor of  
Early Growth Response Factor - 1 Protein (Egr-1).
2. The method of claim 1, wherein the inhibitor is an organic  
10 molecule having a molecular weight from about 500 daltons to  
about 50 kilodaltons.
3. The method of claim 1, wherein the inhibitor is a nucleic acid.
4. The method of claim 1, wherein the inhibitor is a compound  
15 which inhibits activity of Early Growth Response Factor - 1  
Protein (Egr-1) conjugated to a carrier.
5. The method of claim 1, wherein the inhibitor is a compound  
20 which inhibits expression of the Early Growth Response Factor -  
1 Protein (Egr-1) in the cells of the tissue.
6. The method of claim 1, wherein the inhibitor is a nucleic acid  
25 molecule which comprises a polynucleotide sequence  
complementary to the polynucleotide sequence of Early Growth  
Response Factor - 1 mRNA.
7. The method of claim 1, wherein the inhibitor is a peptide, a  
30 peptidomimetic compound, a nucleic acid molecule, a small  
molecule, an organic compound, an inorganic compound, or an  
antibody or a fragment thereof.
8. The method of claim 4, wherein the carrier is a  
pharmaceutically acceptable carrier.

9. The method of claim 1, wherein the tissue is vascular tissue.
10. The method of claim 1, wherein the tissue is a lung, a heart,  
5 a kidney, a vein, an artery, a stomach, a colon, a liver, skin,  
an eye, a pancreas, a finger, a brain, a toe or a limb.
11. The method of claim 1, wherein the contacting of the cells with  
the inhibitor occurs *in vitro*.
- 10 12. The method of claim 1, wherein the ischemic tissue is to be  
transplanted into a subject.
13. The method of claim 1, wherein the tissue has been subjected to  
15 reduced or interrupted blood flow.
14. The method of claim 1, wherein the damage to the ischemic  
tissue comprises cell death, abnormal cell function, abnormal  
cell growth, or inability for cell to maintain normal function.
- 20 15. The method of claim 1, wherein the inhibitor is a nucleic acid  
consisting essentially of the polynucleotide sequence 5'-  
CTTGCCCGCTGCCAT-3' (SEQ ID NO:1).
- 25 16. A method for reducing vascular injury during reperfusion of an  
ischemic tissue in a subject which comprises contacting the  
tissue with a compound which inhibits expression of Early  
Growth Response Factor - 1 (Egr-1) protein in the tissue so as  
to reduce vascular injury in the tissue during reperfusion.
- 30 17. The method of claim 16, wherein the tissue is an ischemic  
tissue.



18. The method of claim 16, wherein the tissue is an organ which is to be transplanted into the subject.
19. The method of claim 16, wherein the tissue is a lung, a heart,  
5 a kidney, a vein, an artery, a stomach, a colon, a liver, skin,  
an eye, a pancreas, a brain, a finger, a toe or a limb.
20. The method of claim 16, wherein the compound is a nucleic acid  
which comprises a polynucleotide sequence complementary to the  
10 polynucleotide sequence of Early Growth Response Factor - 1  
mRNA.
21. The method of claim 16, wherein the compound is a peptide, a  
peptidomimetic compound, a nucleic acid molecule, a small  
15 molecule, an organic compound, an inorganic compound, or an  
antibody or a fragment thereof.
22. The method of claim 16, wherein the subject has suffered a  
stroke, or a myocardial infarction.
23. The method of claim 16, wherein the subject is undergoing  
20 angioplasty, cardiac surgery, vascular surgery, or organ  
transplantation.
24. The method of claim 23, wherein the vascular surgery is  
25 coronary artery surgery.
25. The method of claim 16, wherein the vascular injury comprises  
cell death, abnormal cell function, abnormal cell growth, or  
30 inability for cell to maintain normal function.
26. The method of claim 16, wherein the inhibitor is a nucleic acid  
consisting essentially of the polynucleotide sequence 5'-

5

27. The method of claim 16, wherein the inhibitor is contacted with the tissue before, during or after reperfusion of the ischemic tissue.

Methods to Inhibit the Activity of Early Growth Response - 1  
Protein (Egr-1) To Reduce Vascular Injury In a Subject

5

Abstract of the Disclosure


The invention provides a method for reducing damage to an ischemic tissue which comprises contacting cells of the tissue with an inhibitor of Early Growth Response Factor - 1 Protein (Egr-1). In addition, the invention provides a method for reducing vascular injury during reperfusion of an ischemic tissue in a subject which comprises contacting the tissue with a compound which inhibits expression of Early Growth Response Factor - 1 (Egr-1) protein in the tissue so as to reduce vascular injury in the tissue during reperfusion. wherein the inhibitor is a nucleic acid consisting essentially of the polynucleotide sequence 5'- CTTGGCCGCTGCCAT-3' (SEQ ID NO:1). In one embodiment of the invention, the subject has suffered a stroke, or a myocardial infarction. In another embodiment of the invention, the subject is undergoing or has undergone angioplasty, cardiac surgery, vascular surgery, or organ transplantation.

10

15

20


**A**



**B**


B-1. +/+, Control, ISH

B-2. +/+, I/R, ISH



B-3. +/+, I/R, ISH

B-4. +/+, I/R, F4/80



**C. TF immunostaining**

C-1. +/+, Control

C-2. +/+, I/R

C-3. -/-, Control


C-4. -/-, I/R



Yan et al. Fig. 1A-C


Figure 1 A-C

**D**




**E** E-1. +/+, Control, ISH

E-2. +/+, I/R, ISH



E-3. +/+, I/R, ISH

E-4. +/+, I/R, F4/80



**F. PAI-1 immunostaining**

F-1. +/+, Control

F-2. +/+, I/R


F-3. -/-, Control

F-4. -/-, I/R



Figure 1 D-F


**A**



**B**

B-1. +/+, Control, ISH

B-2. +/+, I/R, ISH



**C. VEGF immunostaining**

C-1. +/+, Control

C-2. +/+, I/R

C-3. -/-, Control

C-4. -/-, I/R





Figure 2 A-C


**A**



**B** B-1. +/+, Control, ISH



B-2. +/+, I/R, ISH



B-3. +/+, I/R, ISH



B-4. +/+, I/R, F4/80




**C. ICAM-1 immunostaining**


C-1. +/+, Control




C-2. +/+, I/R



C-3. -/-, Control




C-4. -/-, I/R



**Figure 3 A-C**

A



B





Figure 4 A-C




D



E

E-1. +/+, Control, ISH

E-2. +/+, I/R, ISH



F




Figure 4 D-F










Figure 4 G-I



**A**





**B**



**Figure 5 A-B**

Figure 5 C-E



**F**

|  |   |   |   |   |   |   |   |   |   |    |    |    |    |    |
|--|---|---|---|---|---|---|---|---|---|----|----|----|----|----|
|  | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
|--|---|---|---|---|---|---|---|---|---|----|----|----|----|----|



**G**

|  |   |   |   |   |   |   |
|--|---|---|---|---|---|---|
|  | 1 | 2 | 3 | 4 | 5 | 6 |
|--|---|---|---|---|---|---|



|           |   |    |    |    |    |    |    |    |    |    |    |    |    |    |
|-----------|---|----|----|----|----|----|----|----|----|----|----|----|----|----|
| I (min)   | 0 | 15 | 30 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 |
| R(min)    | 0 | 0  | 0  | 0  | 60 | 0  | 60 | 0  | 60 | 0  | 60 | 0  | 60 | 60 |
| NE        | - | +  | +  | +  | +  | +  | +  | +  | +  | +  | +  | +  | +  | +  |
| Egr probe | + | +  | +  | +  | +  | +  | +  | +  | +  | +  | +  | +  | +  | +  |
| α Egr-1   | - | -  | -  | -  | -  | +  | +  | -  | -  | -  | -  | -  | -  | -  |
| Cold Sp1  | - | -  | -  | -  | -  | -  | -  | +  | +  | -  | -  | -  | -  | -  |
| Cold Egr  | - | -  | -  | -  | -  | -  | -  | -  | -  | +  | +  | -  | -  | -  |
| NI IgG    | - | -  | -  | -  | -  | -  | -  | -  | -  | -  | -  | +  | +  | +  |

|           |   |    |    |    |    |    |
|-----------|---|----|----|----|----|----|
| I (min)   | 0 | 15 | 30 | 60 | 60 | 60 |
| R(min)    | 0 | 0  | 0  | 0  | 0  | 60 |
| NE        | - | +  | +  | +  | +  | +  |
| Sp1 probe | + | +  | +  | +  | +  | +  |




Figure 5 F-H








Figure 6 A-E

096442389.002500





Figure 8

# Northern Blotting; Egr-1/ $\beta$ -actin







Figure 9

# Western Blotting ; EGR-1



# Northern Blotting; Egr-1/b-actin




Egr-1


b-actin

Figure 10


Figure 11

## Western Blotting ; EGR-1





# Survival Rate



P=0.0226

Figure 13

# DECLARATION AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

## METHODS FOR SUPPRESSING EARLY GROWTH RESPONSE - 1 PROTEIN (Egr-1) TO REDUCE VASCULAR INJURY IN A SUBJECT

the specification of which:  
(check one)

☒ is attached hereto.

☐ was filed on \_\_\_\_\_ as

Application Serial No. \_\_\_\_\_

and was amended \_\_\_\_\_  
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 (a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International Application which designated at least one country other than the United States, listed below. I have also identified below any foreign application for patent or inventor's certificate, or PCT International Application having a filing date before that of the earliest application from which priority is claimed:

Prior Foreign Application(s)

Priority Claimed

| <u>Number</u> | <u>Country</u> | <u>Filing Date</u> | <u>Yes</u> | <u>No</u> |
|---------------|----------------|--------------------|------------|-----------|
| N/A           |                |                    |            |           |
|               |                |                    |            |           |
|               |                |                    |            |           |
|               |                |                    |            |           |
|               |                |                    |            |           |
|               |                |                    |            |           |

005220 62683

Applicants: David Pinsky, David M. Stern and Shi-Fang Yan

U.S. Serial No.: Not Yet Known

Filed: August 25, 2000  
Declaration and Power of Attorney

Page 2

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below:

| <u>Provisional Application No.</u> | <u>Filing Date</u> | <u>Status</u> |
|------------------------------------|--------------------|---------------|
| N/A                                |                    |               |
|                                    |                    |               |
|                                    |                    |               |
|                                    |                    |               |
|                                    |                    |               |

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States Application(s), or Section 365(c) of any PCT International Application(s) designating the United States listed below. Insofar as this application discloses and claims subject matter in addition to that disclosed in any such prior Application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56, which became available between the filing date(s) of such prior Application(s) and the national or PCT international filing date of this application:

| <u>Application Serial No.</u> | <u>Filing Date</u> | <u>Status</u> |
|-------------------------------|--------------------|---------------|
| N/A                           |                    |               |
|                               |                    |               |
|                               |                    |               |
|                               |                    |               |
|                               |                    |               |
|                               |                    |               |

And I hereby appoint

John P. White (Reg. No. 28,678); Christopher C. Dunham (Reg. No. 22,031); Norman H. Zivin (Reg. No. 25,385); Jay H. Maioli (Reg. No. 27,213); William E. Pelton (Reg. No. 25,702); Robert D. Katz (Reg. No. 30,141); Peter J. Phillips (Reg. No. 29,691); Wendy E. Miller (Reg. No. 35,615); Richard S. Milner (Reg. No. 33,970); Robert T. Maldonado (Reg. 38,232); Paul Teng (40,837); Richard F. Jaworski (Reg. No. 33,515); Elizabeth M. Wieckowski (Reg. No. 42,226); Pedro C. Fernandez (Reg. No. 41,741); Gary J. Gershik (Reg. No. 39,992); Jane M. Love (Reg. No. 42,812); Spencer H. Schneider (Reg. No. 45,923) and Raymond A. Diperna (Reg. No. 44,063).

and each of them, all c/o Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, New York 10036, my attorneys, each with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to receive the patent, to transact all business in the Patent and Trademark Office connected therewith and to file any International Applications which are based thereon under the provisions of the Patent Cooperation Treaty.



Please address all communications, and direct all telephone calls, regarding this application to:

John P. White \_\_\_\_\_ Reg. No. 28,678

Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
Tel. (212) 278-0400

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or  
first joint inventor David Pinsky

Inventor's signature \_\_\_\_\_

Citizenship United States Date of signature \_\_\_\_\_

Residence 23 Kennedy Road, Cresskill, New Jersey, 07626, U.S.A.

Post Office Address same as above

Full name of joint  
inventor (if any) David M. Stern

Inventor's signature \_\_\_\_\_

Citizenship United States Date of signature \_\_\_\_\_

Residence 63 Tanners Road, Great Neck, New York, 11020, U.S.A.

Post Office Address same as above

Full name of joint  
inventor (if any) Shi-Fang Yan

Inventor's signature \_\_\_\_\_

Citizenship People's Republic of China Date of signature \_\_\_\_\_

Residence 600 West 165th Street, Apartment 4F, New York, New York 10032, U.S.A.

Post Office Address same as above